

An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 777111.



Deliverable D3.10 "Publication on results of pilot study 2 (HFpEF)"

Work Package WP3 "Clinical validation of in-silico trial prediction"



Disclaimer

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 777111. Any dissemination of results reflects only the author's view and the European Commission is not responsible for any use that may be made of the information it contains.

Copyright message

© REPO-TRIAL Consortium, 2024

This deliverable contains original unpublished work except where clearly indicated otherwise. Acknowledgement of previously published material and of the work of others has been made through appropriate citation, quotation or both. Reproduction is authorised provided the source is acknowledged.

Document information

Grant Agreement Number: 777111				Acronym: REPO-TRIAL		
Full title	An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes					
Торіс	In-silico trials	for de	eveloping and ass	essing biome	dical products	
Funding scheme	RIA - Researd	ch an	d Innovation actio	n		
Start Date	1 February 20)18	Duration	72 months		
Project URL	https://repo-tr	ial.eu	<u>/</u>			
EU Project Officer	Dusan Sando	r, Pro	ogramme Officer, I	European Cor	nmission	
Project Coordinator	Prof. Dr. Hara	ald H.	H.W. Schmidt, Un	iversiteit Maa	stricht (UM)	
Deliverable	D3.10					
Work Package	WP3					
Date of Delivery	Contractual	31.0	01.2024	Actual	28.03.2024	
Nature	R		Dissemination Level	PU		
Lead Beneficiary	12 - MLU					
Responsible Author(s)	Prof. Harald Schmidt (UM)					
Keywords	Publication or	n resu	Its of pilot study			





History of changes

Version	Date	Contributions	Contributors (name and institution)	
			Rafael De la Espriella,	
V0.1	27.03.2024	First draft	Jonathan Schaul,	
			Vanessa Köhler (concentris)	
V1	28.03.2024	Final version	Jonathan Schaul,	
VI	20.03.2024	Final version	Harald Schmidt (UM)	
V1	28.03.2024	Approval	Harald Schmidt (UM)	
V1	28.03.2024	Submission	Vanessa Köhler (concentris)	





Table of Content

1	Ex	xecutive Summary	5
		eliverable Report	
		Patient Characteristics	
	2.2	Safety	7
	2.3	Efficacy	8
3	Att	tachments1	0





1 Executive Summary

This deliverable report provides the study details of the

- REPO-HFpEF I study (full title "Clinical safety evaluation in healthy volunteers of REPurposed citrulline and fOlic acid in combination with vericiguat as a possible treatment in Heart Failure with Preserved Ejection Fraction")
- and REPO-HFpEF II study (full title "Mechanism-based drug REpurPOsing in a subtype of Heart Failure with Preserved Ejection Fraction (REPO-HFPEF)".

Both primary and secondary outcomes, safety and efficacy, have been analysed and achieved. We consider D3.10 as published because all data has been uploaded to a public trial registry (EudraCT) (See Clinical trial Application Forms in the attachment).

The publication in peer-reviewed journals is also planned after the project end and will follow a well thought-through publication strategy. The results are of such impact and broad interest that high impact publications are possible.





2 Deliverable Report

2.1 Patient Characteristics

Between 18 April 2023 and 03 July 2023, a total of 34 patients underwent screening, of whom 21 were randomly assigned to receive Vericiguat, L-Citrulline, and Folate (n=14) or the SOC group (n=7). The last patient completed follow-up on 04 December 2023. All patients provided informed consent. The median age was 80 years [interquartile range 75-87 years], and 71% (n=15) were female. The groups were similar in terms of baseline characteristics (Table 1). Patients in both groups had evidence of elevated natriuretic peptides, with a median N-terminal pro-blood natriuretic peptide (NT-proBNP) of 1378 pg/ml [592–2300], and severely impaired functional capacity, which was evaluated by cardiopulmonary exercise metrics (median Peak VO2 12.3 ml/kg/min [9.4-14]).

Table 1: Baseline characteristics at the time of REPO trial enrollment. Data are given as n (%) or median (IQR)

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; bpm, beats per minute; CA125, carbohydrate antigen 125; E/e', ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity; iLAV, indexed left atrial volume; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonists; NT-proBNP, N-terminal brain natriuretic peptide; peak Vo2, peak oxygen consumption; SGLT2i, sodiumglucose cotransporter 2 inhibitors; VCo2, carbon dioxide production; VE, minute ventilation; VE/VCO2 slope, ventilatory efficiency.

	Usual-care (n=7)	REPO (n=14)	p-value
Age (years)	85 (71-86)	80 (75-87)	0.970
Female	6 (86)	9 (64)	0.306
Body mass index	31 (29-32)	30 (25-34)	0.265
Height, centimeters	157 (155-172)	165 (150-169)	0.487
Hypertension	5 (71)	12 (86)	0.432
Persistent atrial fibrillation	6 (86)	12 (86)	1.000
Diabetes	5 (71)	5 (36)	0.122
Systolic BP (mmHg)	122 (122-145)	131 (120-133)	0.412
Diastolic BP (mmHg)	73 (63-74)	71 (65-78)	1.000
Heart rate (bpm)	72 (65-75)	71 (55-74)	0.502
Medications			
Beta-blocker	4 (57)	10 (71)	0.513
ACEI/ARB	5 (71)	10 (71)	1.000
MRA	4 (57)	2 (14)	0.040
SGLT2i	7 (100)	12 (86)	0.293
Loop Diuretic	6 (86)	12 (86)	1.000
Thiazide	3 (43)	4 (29)	0.513
Laboratory Values			
Hemoglobin, g/dl	14.3 (13.2-15.1)	13.3 (12.2-14.9)	0.456
Creatinine (mg/dl)	1.4 (1.0-1.8)	1.1 (0.8-1.6)	0.351
NT-proBNP (pg/ml)	2257 (1378-3189)	877 (566-1557)	0.101
CA125 (U/ml)	25 (16-29)	16 (15-19)	0.062
Heart Failure Score			
KCCQ	59 (52-72)	72 (52-76)	0.332
Cardiac structure and function			
LVEDD (mm)	44 (36-44)	40 (35-47)	0.593
LVEF (%)	60 (56-69)	61 (60-67)	0.384
LVEF ≥60%	5 (71)	13 (93)	0.186



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 777111.



	Usual-care (n=7)	REPO (n=14)	p-value
iLAV (ml/m2)	55 (34-69)	53 (37-66)	0.667
Average E/e'	14 (10-19)	14 (10-18)	0.323
Cardiopulmonary exercise testing			
Peak VO ₂ (ml/kg/min)	10.6 (7.9-12.3)	13.1 (9.4-14.1)	0.412
VE/VCo ₂ slope	37 (31-44)	33 (26-38)	0.002
Respiratory exchange ratio	1.0 (1.0-1.1)	1.2 (1.1-1.2)	0.019
Chronotropic index	0.46 (0.21-0.74)	0.39 (0.34-0.49)	0.651
Heart rate at exercise peak (beats/min)	102 (80-128)	100 (90-105)	0.795

2.2 Safety

The total count of adverse events (AEs) between treatment groups was 23 in 14 patients in the Vericiguat, L-Citrulline, and Folate group (REPO group) and 6 in 7 patients in the SOC group. Table 2 summarizes AEs by treatment group. Three patients discontinued Vericiguat, L-Citrulline, and Folate due to AEs. Incidence rates between randomization and visit 4 (end of treatment – day 84 \pm 10d from randomization) were 50 per 100 patients/month in the REPO group versus 25 per 100 patients/month in the SOC group (IRR 2.01; 95%CI 0.82-4.93, p=0.126) as illustrated in Figure 1a. When accounting for cardiovascular- and renal-related AEs, there were 13 in 14 patients in the REPO group versus 5 in 7 patients in the SOC group. Incidence rates of cardiovascular- and renal-related AEs between randomization and visit 4 (end of treatment – day 84 \pm 10d from randomization) were 28 per 100 patients/month in the REPO group versus 21 per 100 patients/month in the SOC group (IRR 1.36; 95%CI 0.42-4.67, p=0.606) as illustrated in Figure 1b.




Figure 1: Incidence of adverse events (AEs) in the REPO versus SOC groups. Figure 1a, on the left, illustrates overall AEs. Figure 1b, on the right, shows cardiovascular- and renal-related AEs.

One patient died during the study period in the REPO group. The cause of death was septic shock due to critical ischemia in the right lower limb. The investigator reported no relation to treatment effect p-value. Similarly, no differences were found for changes in serum creatinine (between treatment effect p-value >0.05), NT-proBNP (between treatment effect p-value >0.05), CA125 (between treatment effect p-value >0.05), or serum hemoglobin (between treatment effect p-value >0.05).

Table 2: Overview of Adverse Events between REPO (n=14) and SOC/Usual-care (n=7) treatment groups.

	All (n=21)	Usual-care (n=7)	REPO (n=14)	Fisher p-value
Total AEs	29	6	23	0.178
Accidental fall	2	0	2	0.433
Asthenia	1	0	1	0.667





	All (n=21)	Usual-care (n=7)	REPO (n=14)	Fisher p-value
Dyskalemia	2	0	2	0.433
Gastrointestinal	2	1	1	0.660
Hypercalcemia	1	0	1	0.667
Hypertension	1	1	0	0.333
Hypotension	3	0	3	0.274
Urinary tract infection	2	0	2	0.433
Vascular	1	0	1	0.667
Worsening heart failure	6	3	3	0.445
Worsening renal function	6	1	5	0.624
Fatal event	1	0	1	0.667

2.3 Efficacy

Baseline NOX5 levels positively influence the effectiveness of treatments, as measured by Peak oxygen capacity (Peak VO2), indicating that higher initial levels of NOX5 are associated with better treatment outcomes. Conversely, the baseline sGC ratio shows an inverse relationship with treatment efficacy, as illustrated in Figure 2, where a higher baseline sGC ratio correlates with lesser improvements in Peak VO2.




Figure 2: Comparative and Correlation Analyses of Delta Peak VO2. Upper panels depict the treatment effects on Delta Peak VO2 among groups based on NOX5 (left) and sGC ratio (right) at baseline. Lower panels illustrate correlations between Delta Peak VO2 and NOX5 levels (left), as well as sGC ratio (right), highlighting the impact of these biomarkers on treatment efficacy.





Similarly, when measuring the difference in KCCQ points, baseline levels of NOX5 positively influence the effectiveness of the treatment, suggesting that higher initial levels of NOX5 are associated with greater improvements in patient-reported outcomes related to heart failure symptoms and quality of life. Also here, the baseline sGC ratio exhibits an inverse relationship with treatment efficacy in terms of delta KCCQ points. As illustrated in Figure 3, a higher baseline sGC ratio correlates with lesser improvements in the KCCQ scores.




Figure 3: Comparative and Correlation Analyses of Delta KCCQ Points. The upper panels display the treatment effects on Delta KCCQ points among groups based on NOX5 (left) and sGC ratio (right) at baseline. The lower panels illustrate correlations between Delta KCCQ points and NOX5 levels (left), as well as sGC ratio (right).





3 Attachments

- EudraCT Clinical trial Application Form "Clinical safety evaluation in healthy volunteers of REPurposed citrulline and fOlic acid in combination with vericiguat as a possible treatment in Heart Failure with Preserved Ejection Fraction" (REPO-HFpEF I)
- EudraCT Clinical trial Application Form "Mechanism-based drug REpurPOsing in a subtype of Heart Failure with Preserved Ejection Fraction (REPO-HFPEF)" (REPO-HFPEF II)



REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE COMMUNITY

To be filled in by the applicant

The questions in this form for the request for authorisation from the Competent Authority are also relevant for the opinion from an Ethics Committee (it represents module 1 of the form for applying to an ethics committee) and can be used as part of that application. Please indicate the relevant purpose in a box below.

REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE:

Yes ● No ●

A. TRIAL IDENTIFICATION

A.1 A.2 A.3	EudraCT number: Full title of the trial		Germany - BfArM 2021-005028-39
	English		y volunteers of REPurposed citrulline vericiguat as a possible treatment in ion Fraction
A.3.1	Title of the trial for English		n-technical, language: ine, folic acid and vericugat in healthy n regard to a treatment of patients with
A.3.2	Name or abbreviate English	d title of the trial where available: REPO-HFpEF I	
A.4	Sponsor's protocol	code number, version and date1:	
A.4.1	Sponsor's protocol	code number:	Ph1U_EXT-202001
A.4.2	Sponsor's protocol		2.0
A.4.3	Sponsor's protocol		2021-11-25
A.5 A.5.1	ISRCTN number:	onal study identifiers (e.g. WHO, ISRCTN	V ² , US NCT NUMBER ³) if available
A.5.2	US NCT number:		
A.5.3	WHO Universal Tria	Number (UTN):	
A.5.4	Other Identifier:		
A.6	Is this a resubmissi		No •
		resubmission letter ⁴ : First Submis	
A.7		n agreed Paediatric Investigation Plan?	No •
A.8	EMA Decision numb	er of Paediatric Investigation Plan:	

B. IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

B.1	SPONSOR	
B.1.1	Name of organisation:	Maastricht University
B.1.2	Name of the person to contact:	
B.1.2.1	Given name	Harald
B.1.2.2	Middle name	
B.1.2.3	Family name	Schmidt
B.1.3	Address:	
B.1.3.1	Street address	Universiteitssingel 40
B.1.3.2	Town/city	Maastricht
B.1.3.3	Post code	6229
B.1.3.4	Country	Netherlands
B.1.4	Telephone number:	
B.1.5	Fax number:	
B.1.6	E-mail:	hschmidt@ppmlab.net
B.2		THE SPONSOR IN THE COMMUNITY FOR THE PURPOSE OF
	THIS TRIAL (if different from the	e sponsor)
B.2.1	Name of organisation:	
B.2.2	Name of person to contact:	
B.2.2.1	Given name	
D D D D		
B.2.2.2	Middle name	
B.2.2.3	Middle name Family name	
B.2.2.3 B.2.3 B.2.3.1	Family name	
B.2.2.3 B.2.3	Family name Address:	
B.2.2.3 B.2.3 B.2.3.1	Family name Address: Street address	
B.2.2.3 B.2.3 B.2.3.1 B.2.3.2	Family name Address: Street address Town/city	
B.2.2.3 B.2.3 B.2.3.1 B.2.3.2 B.2.3.3	Family name Address: Street address Town/city Post code	
B.2.2.3 B.2.3 B.2.3.1 B.2.3.2 B.2.3.3 B.2.3.4	Family name Address: Street address Town/city Post code Country	
B.2.2.3 B.2.3 B.2.3.1 B.2.3.2 B.2.3.3 B.2.3.4 B.2.4	Family name Address: Street address Town/city Post code Country Telephone number:	
B.2.2.3 B.2.3 B.2.3.1 B.2.3.2 B.2.3.3 B.2.3.4 B.2.4 B.2.5 B.2.6	Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail:	
B.2.2.3 B.2.3 B.2.3.1 B.2.3.2 B.2.3.3 B.2.3.4 B.2.4 B.2.5 B.2.6 B.3	Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail: STATUS OF THE SPONSOR:	
B.2.2.3 B.2.3 B.2.3.1 B.2.3.2 B.2.3.3 B.2.3.4 B.2.4 B.2.5 B.2.6	Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail:	No • Yes •

B.4	Source(s) of Monetary or Material Support for the clinical trial (repeat as necessary):			
B.4.1	Name of organisation:	EU Commission		
B.4.2	Country:	Belgium		

B.5	Contact point ⁶ designated by the sponsor for further information on the trial			
B.5.1	Name of organisation:	University Hospital Bonn		
B.5.2	Functional name of contact point (e.g. "Clinical Trial Information Desk"):	Studienzentrale (SZB)		
B.5.3	Address:			
B.5.3.1	Street address	Venusberg-Campus 1		
B.5.3.2	Town/city	Bonn		
B.5.3.3	Post code	53227		
B.5.3.4	Country	Germany		
B.5.4	Telephone number:			
B.5.5	Fax number:			
B.5.6	E-mail: (use a functional e-mail address rather than a personal one)	studienzentrale-szb@ukbonn.de		

C. APPLICANT IDENTIFICATION, (please tick the appropriate box)

C.1	REQUEST FOR THE COMPETENT AUTHORITY				
C.1.1	Sponsor				
C.1.2	Legal representative of the sponsor				
C.1.3	Person or organisation author	rised by the sponsor to make the application	Yes •		
C.1.4	Complete the details of the a	pplicant below even if they are provided else	where on the form:		
C.1.4.1	Name of Organisation:	Studienzentrale (SZB), University Hosp	bital Bonn		
C.1.4.2	Name of contact person:				
C.1.4.2.1	Given name	Corinna			
C.1.4.2.2	Middle name				
C.1.4.2.3	Family name	Reineke			
C.1.4.3	Address:				
C.1.4.3.1	Street address	Venusberg-Campus 1			
C.1.4.3.2	Town/city	Bonn			
C.1.4.3.3	Post code	53227			
C.1.4.3.4	Country	Germany			
C.1.4.4	Telephone number:				
C.1.4.5	Fax number:	+49 228 2871 6039			
C.1.4.6	E-mail:	corinna.reineke@ukbonn.de			
C.1.5	Request to receive a copy of	CTA data as XML:			
C.1.5.1	Do you want a copy of the Cl file?	A form data saved on EudraCT as an XML	Yes •		
C.1.5.1.1	If Yes provide the e-mail add	ress(es) to which it should be sent (up to 5 a	ddresses):		
	corinna.reineke@ukbonn.c				
C.1.5.1.2		ia password protected link(s)??	Yes •		
If you ans	If you answer No to question C.1.5.1.2 the .xml file will be transmitted by less secure e-mail link(s)				

D. INFORMATION ON EACH IMP

Information on each 'bulk product' before trial-specific operations (blinding, trial specific packaging and labelling) should be provided in this section for each investigational medicinal product (IMP) being tested including each comparator and each placebo, if applicable. **For placebo go directly to D.8**. If the trial is performed with several products use extra pages and give each product a sequential number in D.1.1. If the product is a combination product, information should be given for each active substance.

D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):

D.1.1	This refers to the IMP number:	PR1
D.1.2	IMP being tested	Yes •
D.1.3	IMP used as a comparator	No •

D.2 STATUS OF THE IMP

D.2.1 Has the IMP to be used in the trial a marketing authorisation? Yes • If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2. If 'Yes', specify the product to be used in the clinical trial: D.2.1.1 Folsan D.2.1.1.1 Trade name EV Product Code (where applicable) D.2.1.1.1.1 Name of the Marketing Authorisation Holder: **Teofarma SRL** D.2.1.1.2 D.2.1.1.3 Marketing Authorisation number (if Marketing 9185.00.00 Authorisation granted by a Member State): D.2.1.1.4 Is the IMP modified in relation to its Marketing Authorisation? Yes • D.2.1.1.4.1 If 'Yes', please specify: study specific labeling The country that granted the Marketing Authorisation D.2.1.2 Germany Is this the Member State concerned with this application? D.2.1.2.1 Yes • Situations where an IMP to be used in the CT has a Marketing Authorisation in the Member State D.2.2 concerned, but the protocol allows that any brand of the IMP with a Marketing Authorisation in that Member State be administered to the trial subjects and it is not possible to clearly identify the IMP(s) in advance of the trial start D.2.2.1 In the protocol, is treatment defined only by active No • substance? D.2.2.1.1 If 'Yes', give active substance in D.3.8 or D.3.9 D.2.2.2 In the protocol, do treatment regimens allow different No • combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS? D.2.2.2.1 If 'Yes', give active substance in D.3.8 or D.3.9 D.2.2.3 The products to be administered as IMPs are defined as Yes • belonging to an ATC group⁹ D.2.2.3.1 If 'Yes', give the ATC group of the applicable authorised codes in the ATC code field (level 3 or the level that can be defined) in D.3.3 D.2.2.4 Other: No • D.2.2.4.1 If 'Yes', please specify:

D.2.3	IMPD submitted:	
D.2.3.1	Full IMPD:	No •
D.2.3.2	Simplified IMPD:	Yes •
D.2.3.3	Summary of product characteristics (SmPC) only:	No •
D.2.4	Has the use of the IMP been previously authorised in a	No •

	clinical trial conducted by the sponsor in the	
	Community?	
D.2.4.1	If 'Yes' specify which Member States:	
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community?	No •
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :	
D.2.6	Has the IMP been the subject of scientific advice related to this clinical trial?	Yes •
D.2.6.1	If 'Yes' to D.2.6, please indicate source of advice and provide a copy in the CTA request:	
D.2.6.1.1	CHMP ¹¹ ?	0 •

Yes •

D.2.6.1.2 National Competent Authority?

D.3	DESCRIPTION OF THE IMP	
D.3.1	Product name where applicable ¹² :	Folsan
D.3.2	Product code where applicable ¹³ :	
D.3.3	ATC codes, if officially registered ¹⁴ :	B03B
D.3.4	Pharmaceutical form (use standard terms):	Tablet
D.3.4.1	Is this a specific paediatric formulation?	No •
D.3.5	Maximum duration of treatment of a subject according	ng to the protocol:
	12 days	
D.3.6	Dose allowed:	
D.3.6.1	For first trial only:	
	Specify per day or total	Not Answered •
	Specify total dose (number and unit):	
	Route of administration (relevant to the first dose):	
D.3.6.2	For all trials	
	Specify per day or total	Total •
	Specify total dose (number and unit):	60 mg milligram(s)
	Route of administration (relevant to the maximum	Oral use
	dose):	
D.3.7	Routes of administration (use standard terms):	Oral use

D.3.8	Name of each active substance (INN or proposed INN Folic acid	if available):	
D.3.9	Other available name for each active substance (provide all available):		
D.3.9.1	CAS ¹⁵ number	-	
D.3.9.2	Current sponsor code		
D.3.9.3	Other descriptive name		
	FOLIC ACID		
D.3.9.4	EV Substance code	SUB07774MIG	
D.3.9.5	Full Molecular formula		
D.3.9.6	Chemical/biological description of the Active Substanc	e	
D.3.10	Strength (specify all strengths to be used):		
D.3.10.1	Concentration unit:	mg milligram(s)	
D.3.10.2	Concentration type ("exact number", "range", "more	equal	
	than" or "up to"):		
D.3.10.3	Concentration (number).	5	
D.3.11	Type of IMP		
Does the IM	P contain an active substance:		
D.3.11.1	Of chemical origin? Yes •		
D.3.11.2	Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP)?	No •	
Is this a:			

D.3.11.3 D.3.11.3.1 D.3.11.3.2 D.3.11.3.3 D.3.11.3.4	Advanced Therapy IMP (ATIMP)? Somatic cell therapy medicinal product ¹⁶ ? Gene therapy medicinal product ¹⁷ ? Tissue Engineered Product ¹⁸ ? Combination ATIMP (i.e. one involving a medical device ¹⁹)?	No • No • No • No •
D.3.11.3.5	Has the Committee on Advanced Therapies issued a classification for this product?	No •
D.3.11.3.5.1	If 'Yes' please provide that classification and its reference	ce number:
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy?	No •
D.3.11.5	Radiopharmaceutical medicinal product?	No •
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)?	No •
D.3.11.7	Plasma derived medicinal product?	No •
D.3.11.8	Extractive medicinal product?	No •
D.3.11.9	Recombinant medicinal product?	No •
D.3.11.10	Medicinal product containing genetically modified organisms?	No •
D.3.11.10.1	Has the authorisation for contained use or release been granted?	No •
D.3.11.10.2	Is it pending?	No •
D.3.11.11	Herbal medicinal product?	No •
D.3.11.12	Homeopathic medicinal product?	No •
D.3.11.13	Another type of medicinal product?	No •
D.3.11.13.1	If 'another type of medicinal product' specify the type of	of medicinal product:
D.3.12	Mode of action (<i>free text</i> ²⁰)	
D.3.13 D.3.13.1	Is it an IMP to be used in a first-in-human clinical trial? If 'Yes', are there risk factors identified, according to the	No ● e guidance FIH? ²¹

SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC **D.4 MODIFICATION)** D.4.1 Origin of cells D.4.1.1 Autologous No • D.4.1.2 Allogeneic No • D.4.1.3 Xenogeneic No • D.4.1.3.1 If 'Yes', specify the species of origin: D.4.2 Type of cells D.4.2.1 Stem cells No • D.4.2.2 Differentiated cells No • D.4.2.2.1 If 'Yes', specify the type (e.g. keratinocytes, fibroblasts, chondrocytes...): D.4.2.3 Others: No • D.4.2.3.1 If others, specify:

D.5	GENE THERAPY INVESTIGATIONAL MEDICINAL PRODUCTS		
D.5.1	Gene(s) of interest:		
D.5.2	In vivo gene therapy:	No •	
D.5.3	Ex vivo gene therapy:	No •	
D.5.4	Type of gene transfer product		
D.5.4.1	Nucleic acid (e.g. plasmid): If 'Yes', specify if:	No •	
D.5.4.1.1	Naked:	No •	
D.5.4.1.2	Complexed	No •	
D.5.4.2	Viral vector:	No •	

D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus, AAV,	:	
D.5.4.3 D.5.4.3.1	Others If others, specify:	No ●	
D.5.5 If 'Yes', speci	Genetically modified somatic cells: fy the origin of the cells:	No •	
D.5.5.1	Autologous:	No •	
D.5.5.2	Allogeneic:	No •	
D.5.5.3	Xenogeneic:	No •	
D.5.5.3.1	If 'Yes', specify the species of origin:		
D.5.5.4	Specify type of cells (hematopoietic stem cells):		

D.6 TISSUE ENGINEERED PRODUCT The indication which determines that this is a Tissue Engineered Product as opposed to a Cell Therapy product is given in section E.1.1. D.6.1 Origin of cells Autologous D.6.1.1 No • D.6.1.2 Allogeneic No • D.6.1.3 Xenogeneic No • D.6.1.3.1 If 'Yes', specify the species of origin: D.6.2 Type of cells D.6.2.1 Stem cells No • D.6.2.2 Differentiated cells No • D.6.2.2.1 If 'Yes', specify the type of cells(e.g. keratinocytes, fibroblasts, chondrocytes, ...): D.6.2.3 Others: No •

D.6.2.3.1 If others, specify:

D.7	PRODUCTS CONTAINING DEVICES (i.e. MEDICAL DEVICES, SCAFFOLDS ETC.)	
D.7.1	Give a brief description of the device:	
D.7.2	What is the name of the device?	
D.7.3	Is the device implantable?	No •
D.7.4	Does this product contain:	
D.7.4.1	A medical device?	No •
D.7.4.1.1	Does this medical device have a CE mark?	No •
D.7.4.1.1.1	The notified body is:	
D.7.4.2	Bio-materials?	No •
D.7.4.3	Scaffolds?	No •
D.7.4.4	Matrices?	No •
D.7.4.5	Other?	No •
D.7.4.5.1	If other, specify:	

D.1 IMP IDENTIFICATION Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n): D.1.1 This refers to the IMP number: PR2 D.1.2 IMP being tested Yes • D.1.3 IMP used as a comparator No •

D.2.1 Has the IMP to be used in the trial a marketing authorisation? **Yes** •

If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.

D.2.1.1	If 'Yes', specify the product to be used in the clinical trial:	
D.2.1.1.1	Trade name Stimol	
D.2.1.1.1.1	EV Product Code (where applicable)	
D.2.1.1.2	Name of the Marketing Authorisation Holder:	BIOCODEX
D.2.1.1.3	Marketing Authorisation number (if Marketing	3400933452025
	Authorisation granted by a Member State):	
D.2.1.1.4	Is the IMP modified in relation to its Marketing Authorisatio	on? Yes ●
D.2.1.1.4.1	If 'Yes', please specify:	
	study specific labeling	
D.2.1.2	The country that granted the Marketing Authorisation	France
D.2.1.2.1	Is this the Member State concerned with this application?	No •
D.2.2	Situations where an IMP to be used in the CT has a Market	ing Authorisation in the Member State
	concerned, but the protocol allows that any brand of the IN	
	that Member State be administered to the trial subjects an	
	the IMP(s) in advance of the trial start	, .
D.2.2.1	In the protocol, is treatment defined only by active	No •
	substance?	
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.2	In the protocol, do treatment regimens allow different	No •
	combinations of marketed products used according to	
	local clinical practice at some or all investigator sites in	
	the MS?	
D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.3	The products to be administered as IMPs are defined as	Yes •
	belonging to an ATC group ⁹	
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised co	des in the ATC code field (level 3 or
	the level that can be defined) in D.3.3	,
D.2.2.4	Other:	No •
D.2.2.4.1	If 'Yes', please specify:	
D.2.3	IMPD submitted:	
D.2.3.1	Full IMPD:	No •
D.2.3.2	Simplified IMPD:	Yes •
D.2.3.3	Summary of product characteristics (SmPC) only:	No •
D.2.4	Has the use of the IMP been previously authorised in a	No •
1		

	clinical trial conducted by the sponsor in the	
	Community?	
D.2.4.1	If 'Yes' specify which Member States:	
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community?	No •
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :	

D.2.6	Has the IMP been the subject of sci to this clinical trial?	ntific advice related Yes •
D.2.6.1	If 'Yes' to D.2.6, please indicate sou	rce of advice and provide a copy in the CTA request:
D.2.6.1.1	CHMP ¹¹ ?	No •
D.2.6.1.2	National Competent Authority?	Yes •

D.3DESCRIPTION OF THE IMPD.3.1Product name where applicable12:D.3.2Product code where applicable13:D.3.3ATC codes, if officially registered14:D.3.4Pharmaceutical form (use standard terms):Solution for use in drinking water

D.3.4.1 D.3.5	Is this a specific paediatric formulation? Maximum duration of treatment of a subject according 12 days	No ● to the protocol:
D.3.6 D.3.6.1	Dose allowed: For first trial only: Specify per day or total Specify total dose (number and unit): Route of administration (relevant to the first dose):	Total •
D.3.6.2	For all trials Specify per day or total Specify total dose (number and unit): Route of administration (relevant to the maximum	Total ∙ 72 g gram(s) Oral use
D.3.7	dose): Routes of administration (use standard terms):	Oral use
D.3.8	Name of each active substance (INN or proposed INN i Citrulline Malate	f available):
D.3.9 D.3.9.1	Other available name for each active substance (provi CAS ¹⁵ number	de all available): 70796-17-7
D.3.9.2 D.3.9.3 D.3.9.4	Current sponsor code Other descriptive name CITRULLINE MALATE EV Substance code	SUB13385MIG
D.3.9.4 D.3.9.5	Full Molecular formula	30013303MIG
D.3.9.6	Chemical/biological description of the Active Substance	2
D.3.10	Strength (specify all strengths to be used):	
D.3.10.1 D.3.10.2	Concentration unit: Concentration type ("exact number", "range", "more	g gram(s) equal
D.3.10.3	than" or "up to"): Concentration (number).	1
D.3.11	Type of IMP	
	contain an active substance:	
D.3.11.1 D.3.11.2	Of chemical origin? Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP)?	Yes ● No ●
Is this a:		
D.3.11.3	Advanced Therapy IMP (ATIMP)?	No • No •
D.3.11.3.1	Somatic cell therapy medicinal product ¹⁶ ? Gene therapy medicinal product ¹⁷ ?	
D.3.11.3.2		No •
D.3.11.3.3	Tissue Engineered Product ¹⁸ ?	No •
	Tissue Engineered Product ¹⁸ ? Combination ATIMP (i.e. one involving a medical	
D.3.11.3.3 D.3.11.3.4 D.3.11.3.5	Tissue Engineered Product ¹⁸ ? Combination ATIMP (i.e. one involving a medical device ¹⁹)? Has the Committee on Advanced Therapies issued a classification for this product?	No • No •
D.3.11.3.3 D.3.11.3.4	Tissue Engineered Product ¹⁸ ? Combination ATIMP (i.e. one involving a medical device ¹⁹)? Has the Committee on Advanced Therapies issued a	No • No •
D.3.11.3.3 D.3.11.3.4 D.3.11.3.5 D.3.11.3.5.1 D.3.11.4	Tissue Engineered Product ¹⁸ ? Combination ATIMP (i.e. one involving a medical device ¹⁹)? Has the Committee on Advanced Therapies issued a classification for this product? If 'Yes' please provide that classification and its refere Combination product that includes a device, but does not involve an Advanced Therapy?	No • No • No • Ince number: No •
D.3.11.3.3 D.3.11.3.4 D.3.11.3.5 D.3.11.3.5.1	Tissue Engineered Product ¹⁸ ? Combination ATIMP (i.e. one involving a medical device ¹⁹)? Has the Committee on Advanced Therapies issued a classification for this product? If 'Yes' please provide that classification and its refere Combination product that includes a device, but does not involve an Advanced Therapy? Radiopharmaceutical medicinal product? Immunological medicinal product (such as vaccine,	No • No • No •
D.3.11.3.3 D.3.11.3.4 D.3.11.3.5 D.3.11.3.5.1 D.3.11.4 D.3.11.5	Tissue Engineered Product ¹⁸ ? Combination ATIMP (i.e. one involving a medical device ¹⁹)? Has the Committee on Advanced Therapies issued a classification for this product? If 'Yes' please provide that classification and its refere Combination product that includes a device, but does not involve an Advanced Therapy? Radiopharmaceutical medicinal product?	No • No • No • Ince number: No • No •
D.3.11.3.3 D.3.11.3.4 D.3.11.3.5 D.3.11.3.5.1 D.3.11.4 D.3.11.5 D.3.11.6 D.3.11.7 D.3.11.8	Tissue Engineered Product ¹⁸ ? Combination ATIMP (i.e. one involving a medical device ¹⁹)? Has the Committee on Advanced Therapies issued a classification for this product? If 'Yes' please provide that classification and its refere Combination product that includes a device, but does not involve an Advanced Therapy? Radiopharmaceutical medicinal product? Immunological medicinal product (such as vaccine, allergen, immune serum)? Plasma derived medicinal product? Extractive medicinal product?	No • No • No • No • No • No • No • No •
D.3.11.3.3 D.3.11.3.4 D.3.11.3.5 D.3.11.3.5.1 D.3.11.4 D.3.11.5 D.3.11.6 D.3.11.7	Tissue Engineered Product ¹⁸ ? Combination ATIMP (i.e. one involving a medical device ¹⁹)? Has the Committee on Advanced Therapies issued a classification for this product? If 'Yes' please provide that classification and its refere Combination product that includes a device, but does not involve an Advanced Therapy? Radiopharmaceutical medicinal product? Immunological medicinal product (such as vaccine, allergen, immune serum)? Plasma derived medicinal product?	No • No • No • Ince number: No • No • No •

Ì	been granted?	
D.3.11.10.2	Is it pending?	No •
D.3.11.11	Herbal medicinal product?	No •
D.3.11.12	Homeopathic medicinal product?	No •
D.3.11.13	Another type of medicinal product?	No •
D.3.11.13.1	If 'another type of medicinal product' specify the type of	medicinal product:
D.3.12	Mode of action (<i>free text</i> ²⁰)	
D.3.13 D 3 13 1	Is it an IMP to be used in a first-in-human clinical trial? If 'Yes' are there risk factors identified, according to the	No •

D.3.13.1 If 'Yes', are there risk factors identified, according to the guidance FIH?²¹

D.4 SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC MODIFICATION)

D.4.1	Origin of cells		
D.4.1.1	Autologous	No •	
D.4.1.2	Allogeneic	No •	
D.4.1.3	Xenogeneic	No •	
D.4.1.3.1	If 'Yes', specify the species of origin:		
D.4.2	Type of cells		
D.4.2.1	Stem cells	No •	
D.4.2.2	Differentiated cells	No •	
D.4.2.2.1	If 'Yes', specify the type (e.g. keratine	cytes, fibroblasts, chondrocytes):	
D.4.2.3 D.4.2.3.1	Others: If others, specify:	No •	

D.5	GENE THERAPY INVESTIGATIONAL MEDICI	NAL PRODUCTS	
D.5.1	Gene(s) of interest:		
D.5.2	In vivo gene therapy:	No •	
D.5.3	Ex vivo gene therapy:	No •	
D.5.4	Type of gene transfer product		
D.5.4.1	Nucleic acid (e.g. plasmid):	No •	
	If 'Yes', specify if:		
D.5.4.1.1	Naked:	No •	
D.5.4.1.2	Complexed	No •	
D.5.4.2	Viral vector:	No •	
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus,	AAV,:	
D.5.4.3	Others	No •	
D.5.4.3.1	If others, specify:		
D.5.5	Genetically modified somatic cells:	No •	
If 'Yes', spe	cify the origin of the cells:		
D.5.5.1	Autologous:	No •	
D.5.5.2	Allogeneic:	No •	
D.5.5.3	Xenogeneic:	No •	
D.5.5.3.1	If 'Yes', specify the species of origin:		
D.5.5.4	Specify type of cells (hematopoietic stem cells):	

D.6 TISSUE ENGINEERED PRODUCT

The indication which determines that this is a Tissue Engineered Product as opposed to a Cell Therapy product is given in section E.1.1.

D.6.1	Origin of cells	
D.6.1.1	Autologous	No •
D.6.1.2	Allogeneic	No •
1	5	

D.6.1.3 D.6.1.3.1	Xenogeneic If 'Yes', specify the species of origin:	No •
D.6.2 D.6.2.1 D.6.2.2 D.6.2.2.1	Type of cells Stem cells No • Differentiated cells No • If 'Yes', specify the type of cells(e.g. keratinocytes, fibroblasts, chondrocytes,):	
D.6.2.3 D.6.2.3.1	Others: No •	
D.7	PRODUCTS CONTAINING DEVICES (i.e. MEDICA Give a brief description of the device:	L DEVICES, SCAFFOLDS ETC.)

D.7.2 What is the name of the device?

DIVIE		
D.7.3	Is the device implantable?	No •
D.7.4	Does this product contain:	
D.7.4.1	A medical device?	No ●
D.7.4.1.1	Does this medical device have a CE mark?	No •
D.7.4.1.1.1	The notified body is:	
D.7.4.2	Bio-materials?	No •
D.7.4.3	Scaffolds?	No ●
D.7.4.4	Matrices?	No •
D.7.4.5	Other?	No •
D.7.4.5.1	If other, specify:	

D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):

D.1.1	This refers to the IMP number:	PR3
D.1.2	IMP being tested	Yes •
D.1.3	IMP used as a comparator	No •

D.2 STATUS OF THE IMP

D.2.1 Has the IMP to be used in the trial a marketing authorisation? Yes • If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.

D.2.1.1	If 'Yes', specify the product to be used in the clinical trial:	
D.2.1.1.1	Trade name Verquvo 10mg Filmtabletten	
D.2.1.1.1.1	EV Product Code (where applicable)	
D.2.1.1.2	Name of the Marketing Authorisation Holder:	Bayer AG
D.2.1.1.3	Marketing Authorisation number (if Marketing	EU/1/21/1561/026
	Authorisation granted by a Member State):	
D.2.1.1.4	Is the IMP modified in relation to its Marketing Authorisation	n? Yes •
D.2.1.1.4.1	If 'Yes', please specify:	
	study specific labeling	
1		
D.2.1.2	The country that granted the Marketing Authorisation	Germany
D.2.1.2 D.2.1.2.1	The country that granted the Marketing Authorisation Is this the Member State concerned with this application?	Germany Yes ∙
D.2.1.2.1	Is this the Member State concerned with this application?	Yes •
		Yes • ng Authorisation in the Member State IP with a Marketing Authorisation in

	substance?	
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.2	In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS?	No ∙
D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.3	The products to be administered as IMPs are defined as belonging to an ATC group ⁹	Yes •
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised c the level that can be defined) in D.3.3	odes in the ATC code field (level 3 or
D.2.2.4	Other:	No •
D.2.2.4.1	If 'Yes', please specify:	
D.2.3	IMPD submitted:	
D 2 2 1		No.

D.Z.3			
D.2.3.1	Full IMPD:	No •	
D.2.3.2	Simplified IMPD:	Yes •	
D.2.3.3	Summary of product characteristics (SmPC) only:	No •	
D.2.4	Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community?	No ∙	
D.2.4.1	If 'Yes' specify which Member States:		
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community?	No •	
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :		

D.2.6	Has the IMP been the subject of scientific advice related Yes • to this clinical trial?		
D.2.6.1	If 'Yes' to D.2.6, please indicate source of advi	ce and provide a copy in the CTA request:	
D.2.6.1.1	CHMP ¹¹ ?	No ●	
D.2.6.1.2	National Competent Authority?	Yes •	

D.3	DESCRIPTION OF THE IMP	
D.3.1	Product name where applicable ¹² :	
D.3.2	Product code where applicable ¹³ :	
D.3.3	ATC codes, if officially registered ¹⁴ :	C01DX22
D.3.4	Pharmaceutical form (use standard terms):	
D.3.4.1	Is this a specific paediatric formulation?	No •
D.3.5	Maximum duration of treatment of a subject accordin	g to the protocol:
D.3.6	Dose allowed:	
D.3.6.1	For first trial only:	
	Specify per day or total	Total •
	Specify total dose (number and unit):	
	Route of administration (relevant to the first dose):	
D.3.6.2	For all trials	
	Specify per day or total	Total •
	Specify total dose (number and unit):	60 mg milligram(s)
	Route of administration (relevant to the maximum	Oral use
	dose):	
D.3.7	Routes of administration (use standard terms):	Oral use

D.3.8	Name of each active substance (INN or proposed INN if available): Vericiguat
D.3.9	Other available name for each active substance (provide all available):
D.3.9.1	CAS ¹⁵ number
D.3.9.2	Current sponsor code

D.3.9.3	Other descriptive name Vericiguat	
D.3.9.4	EV Substance code	SUB189401
D.3.9.5	Full Molecular formula	
0.3.9.5		
D.3.9.6	Chemical/biological description of the Active Substance	e
D.3.10	Strength (specify all strengths to be used):	
D.3.10.1	Concentration unit:	mg milligram(s)
D.3.10.2	Concentration type ("exact number", "range", "more	equal
	than" or "up to"):	
D.3.10.3	Concentration (number).	10
D.3.11	Type of IMP	
Door the IMD	contain an active substance:	
		Yes •
D.3.11.1	Of chemical origin?	No •
D.3.11.2	Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP)?	
Is this a:	Advanced merupy init (Attimp):	
D.3.11.3	Advanced Therapy IMP (ATIMP)?	No •
D.3.11.3.1	Somatic cell therapy medicinal product ¹⁶ ?	No •
D.3.11.3.2	Gene therapy medicinal product ¹⁷ ?	No •
D.3.11.3.3	Tissue Engineered Product ¹⁸ ?	No •
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device ¹⁹)?	No •
D.3.11.3.5	Has the Committee on Advanced Therapies issued a	No •
	classification for this product?	
D.3.11.3.5.1	If 'Yes' please provide that classification and its refere	ence number:
D.3.11.4	Combination product that includes a device, but does	No •
	not involve an Advanced Therapy?	
D.3.11.5	Radiopharmaceutical medicinal product?	No •
D.3.11.6	Immunological medicinal product (such as vaccine,	No •
	allergen, immune serum)? Plasma derived medicinal product?	No •
D.3.11.7 D.3.11.8	Extractive medicinal product?	No •
D.3.11.9	Recombinant medicinal product?	No •
D.3.11.10	Medicinal product containing genetically modified	No •
0.3.11.10	organisms?	
D.3.11.10.1	Has the authorisation for contained use or release	No •
01011111011	been granted?	
D.3.11.10.2	Is it pending?	No •
D.3.11.11	Herbal medicinal product?	No •
D.3.11.12	Homeopathic medicinal product?	No •
D.3.11.13	Another type of medicinal product?	No •
D.3.11.13.1	If 'another type of medicinal product' specify the type	e of medicinal product:
D.3.12	Mode of action (free text ²⁰)	
D.3.13	Is it an IMP to be used in a first-in-human clinical tria	l? No ●
0.2.12		

D.4 SOMATIC CELL THERAPY INVESTIGATIONAL I MODIFICATION)		L MEDICINAL PRODUCT (NO GENETIC
D.4.1	Origin of cells	
D.4.1.1	Autologous	No •
D.4.1.2	Allogeneic	No •
D.4.1.3	Xenogeneic	No •
D.4.1.3.1	If 'Yes', specify the species of origin:	

D.4.2	Type of cells	
D.4.2.1	Stem cells	No •
D.4.2.2	Differentiated cells	No •
D.4.2.2.1	If 'Yes', specify the type (e.g. keratinod	cytes, fibroblasts, chondrocytes):
D.4.2.3	Others:	No •
D.4.2.3.1	If others, specify:	
D.5	GENE THERAPY INVESTIGATIONAL	MEDICINAL PRODUCTS
D.5.1	Gene(s) of interest:	
D.5.2	In vivo gene therapy:	No ●
D.5.3	Ex vivo gene therapy:	No •
D.5.4	Type of gene transfer product	
D.5.4.1	Nucleic acid (e.g. plasmid): If 'Yes', specify if:	No •
D.5.4.1.1	Naked:	No •
D.5.4.1.2	Complexed	No •
D.5.4.2	Viral vector:	No •
D.5.4.2.1	If 'Yes', specify the type: adenovirus, r	
D.5.4.3	Others	No •
D.5.4.3.1	If others, specify:	
D.5.5	Genetically modified somatic cells:	No •
	cify the origin of the cells:	
D.5.5.1	Autologous:	No •
D.5.5.2	Allogeneic:	No •
D.5.5.3	Xenogeneic:	No •
D.5.5.3.1	If 'Yes', specify the species of origin:	
D.5.5.4	Specify type of cells (hematopoietic ste	em cells):
	TISSUE ENGINEERED PRODUCT	
		Engineered Product as opposed to a Cell Therapy product
D.6.1	Origin of cells	
D.6.1.1	Autologous	No •
D.6.1.2	Allogeneic	No ●
D.6.1.3	Xenogeneic	No •
D.6.1.3.1	If 'Yes', specify the species of origin:	
D.6.2	Type of cells	
D.6.2.1	Stem cells	No •
D.6.2.2	Differentiated cells	No •
D.6.2.2.1	If 'Yes', specify the type of cells(e.g. ke	eratinocytes, fibroblasts, chondrocytes,):
D.6.2.3	Others:	No •

D.7 PRODUCTS CONTAINING DEVICES (i.e. MEDICAL DEVICES, SCAFFOLDS ET		CAL DEVICES, SCAFFOLDS ETC.)
D.7.1	Give a brief description of the device:	
D.7.2	What is the name of the device?	
D.7.3	Is the device implantable?	No •
D.7.4	Does this product contain:	
D.7.4.1	A medical device?	No •
D.7.4.1.1	Does this medical device have a CE mark?	No •
D.7.4.1.1.1	The notified body is:	
D.7.4.2	Bio-materials?	No •
D.7.4.3	Scaffolds?	No •
D.7.4.4	Matrices?	No •
D.7.4.5	Other?	No •
D.7.4.5.1	If other, specify:	

D.8 INFORMATION ON PLACEBO (if relevant; repeat as necessary)

D.8.1	Is there a placebo:	No •
D.8.2	This refers to placebo number:	
D.8.3	Pharmaceutical form:	
D.8.4	Route of administration:	
D.8.5	Which IMP is it a placebo for? Specify IMP Number	(s) from D.1.1
D.8.5.1	Composition, apart from the active substance(s):	
D.8.5.2	Is it otherwise identical to the IMP?	Yes ? No ? Not Answered ?
D.8.5.2.1	If not, specify major ingredients:	

D.9 SITE(S) WHERE THE QUALIFIED PERSON CERTIFIES BATCH RELEASE²²

This section is dedicated to **finished** IMPs, i.e. medicinal products randomised, packaged, labelled and certified for use in the clinical trial. If there is more than one site or more than one IMP is certified, use extra pages and give each IMP its number from section D.1.1 or D.8.2 In the case of multiple sites indicate the product certified by each site

D.9.1	Do not fill in section D.9.2 for an IMP that:
D.9.1	
	Has a MA in the EU and
	<i>Is sourced from the EU market_and</i>
	Is used in the trial without modification(e.g. not overencapsulated) _and
	The packaging and labelling is carried out for local use only as per article 9.2. of the Directive
	2005/28/EC (GCP Directive)
	If all these conditions are met tick • and list the number(s) of each IMP including placebo from
	sections D.1.1 and D.8.2 to which this applies
	PR1
	PR2
	PR3

D.9.2 Who is responsible in the Community for the certification of the finished IMPs?

This site is responsible for certification of (list the number(s) of each IMP including placebo from sections $D_1 + 1$ and $D_2 + 2$):	PR1 PR2 PR3
number(s) of each IMP including placebo from sections D.1.1 and D.8.2):	PR2 PR3

	please tick the appropriate box:	
D.9.2.1 D.9.2.2 D.9.2.3	Manufacturer Importer Name of the organisation:	Yes ● No ● Manufacturing Unit, Hospital Pharmacy, University Hospital Heidelberg
D.9.2.4 D.9.2.4.1 D.9.2.4.2 D.9.2.4.3 D.9.2.4.4 D.9.2.5 D.9.2.5.1	Address: Street Address Town/City Post Code Country Give the manufacturing authorisation number: If No authorisation, give the reasons:	Im Neuenheimer Feld 670 Heidelberg 69120 Germany DE_BW_01_MIA_2016_0005

Where the product does not have a MA in the EU, but is supplied in bulk and final packaging and labelling for local use is carried out in accordance with article 9.2 of Directive 2005/28/EC (GCP Directive) then enter the site where the product was finally certified for release by the Qualified Person for use in the clinical trial at D.9.2 above.

E. GENERAL INFORMATION ON THE TRIAL

This section should be used to provide information about the aims, scope and design of the trial. When the protocol includes a sub-study in the MS concerned section E.2.3 should be completed providing information about the sub-study. To identify it check the sub-study box in the 'Objective of the trial' question below.

E.1	MEDICAL CONDITION OR DISEASE UNDER INVESTIGATION	
E.1.1	Specify the medical condition(s) to be investigated23 (free text):EnglishSafety and tolerability in healthy subjects	
E.1.1.1	Medical condition in easily understood languageEnglishSafety and tolerability in healthy subjects	
E.1.1.2	Therapeutic area Not possible to specify	
E.1.2	MedDRA version, system organ class, level, term and classification code ²⁴ : Version System Organ Class Classification Code Term Level	
E.1.3	Is any of the conditions being studied a rare disease ²⁵ ? No •	
E.2	OBJECTIVE OF THE TRIAL	
E.2.1	Main objective:EnglishTo assess the safety and tolerability of citrulline and folic acid in combination with vericiguat	
E.2.2	Secondary objectives: English Not applicable	
E.2.3 E.2.3.1	Is there a sub-study? No \bullet If 'Yes', give the full title, date and version of each sub-study and their related objectives:	
E.3	PRINCIPAL INCLUSION CRITERIA (list the most important)	
	 English Subjects male or female, aged equal 18 years or above given written consent to participate in the study. Ability to provide written, personally signed, and dated informed consent to participate in the trial, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6, and applicable regulations, prior to any trial-related interventions. 	

E.4	PRINCIPAL EXCLUSION CRITERIA (list the most important)	
	English	 Subject without legal capacity who is unable to understand the nature, scope, significance and consequences of this clinical trial Clinically significant or relevant abnormalities in the medical history, physical examination (e.g. heart murmur), ECG and laboratory evaluation as assessed by the investigator, Medical disorder that may make the participant unlikely to fully complete the trial, or any condition that presents undue risk from the IMP or trial interventions as judged by the investigator, Clinically relevant ongoing or clinically relevant history of physical or psychiatric illness as judged by the investigator, Blood pressure < 110/>140 mmHg systolic or < 50/>100 mmHg diastolic, or medical history of orthostatic dysregulation or pathologic response to hemodynamic profile at Screening defined as a difference o >20 mmHg in the systolic pressure between the supine and the standing

position

	position • \Box History of previous syncope during the last 3 months prior to
	screening visit
	• Resting heart rate < 50 bpm or > 90 bpm
	 QTc prolongation (males > 450ms, females > 460ms) Atrioventricular block II and III degree
	• History of bleeding disorders
	• Acute or chronic illness or clinically relevant finding known or
	expected to modify absorption, distribution, metabolism, or excretion of
	vericiguat, citrulline or folate/folic acid,
	 History of hereditary galactose intolerance, lactase deficiency, or glucose-galactose malabsorption
	• Clinically relevant findings in any of the following investigations
	(minor deviations of laboratory values from the normal range can be
	acceptable, if judged by the investigator to be of no clinical relevance
	for this trial):
	o□Haemoglobin (Hb) < 12 g/dl (males) or < 11 g/dl (females), o□Creatine kinase (CK) not within normal limits (subjects with CK
	elevations between ULN and ULN x 3 may be included if troponin T is
	negative)
	 Subjects with a physical or psychiatric condition which at the
	investigator's discretion may put the subject at risk, may confound the
	trial results, or may interfere with the subject's participation in this clinical trial
	• Known or persistent abuse of medication, drugs or alcohol
	Exclusion criteria regarding special restrictions for females:
	• Current (positive pregnancy test, e.g. ß-HCG test in serum or urine) or
	planned pregnancy or nursing women
	• Females of childbearing potential, who are not using and not willing to use medically reliable methods of contraception for the entire study
	duration (such as oral, injectable, or implantable contraceptives, or
	intrauterine contraceptive devices) unless they are surgically sterilized /
	hysterectomized or there are any other criteria considered sufficiently
	reliable by the investigator in individual cases
	Indication specific exclusion criteria: • — Known history of hypersensitivity to the investigational drug or to
	drugs with a similar chemical structure, e.g. arginine or riociguat
	• Creatinine (Crea) clearance (Cl) < 90 ml/min (CKD-EPI-Formel),
	• \Box Bilirubin > upper limit of normal (ULN) x 1.2; In case of suspected
	Gilbert's disease: non fasting total bilirubin \leq ULN x 1.2 and fasting total
	bilirubin ≤ ULN x 1.5 are acceptable. • \Box Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST)
	> ULN x 1.5
	• Concomitant use of medications/drugs that interact
	pharmacologically with the investigational drugs (e.g. PDE5 inhibitors,
	nitrates)
	• Use of an IMP within 30 d or five times the half-life of the IMP, whichever is longer prior to the expected date of receiving the first dose
	of IMP or active enrolment in another drug or vaccine clinical trial.
	• A positive result in a drug screening test,
	• Intake of medication with impact on platelet function (e.g. NSAIDs)
	within two weeks prior to the first dose of IMP
	• Specific contraindications to folate/folic acid: megaloblastic anemia as indication of vitamin B12 deficiency
FND POINT(S)	

E.5	END POINT(S	.):
E.5.1	Primary End Po	pint (repeat as necessary) ²⁶
	English	●□Laboratory safety data

●□Vital signs ●□Adverse events, especially hypotension, syncope

- E.5.1.1 Timepoint(s) of evaluation of this end point English Day 1, Day 7, Day 12, Day 20 (only AEs)
- E.5.2 Secondary End Point (repeat as necessary) English Not applicable
- E.5.2.1 Timepoint(s) of evaluation of this end point English Not applicable

E.6	SCOPE OF THE TRIAL – Tick all boxes where applicable		
E.6.1	Diagnosis	No ●	
E.6.2	Prophylaxis	No •	
E.6.3	Therapy	No •	
E.6.4	Safety	Yes •	
E.6.5	Efficacy	No •	
E.6.6	Pharmacokinetic	No •	
E.6.7	Pharmacodynamic	No •	
E.6.8	Bioequivalence	No •	
E.6.9	Dose Response	No •	
E.6.10	Pharmacogenetic	No •	
E.6.11	Pharmacogenomic	No •	
E.6.12	Pharmacoeconomic	No •	
E.6.13	Others	No •	
E.6.13.1	If others, specify:		

E.7	TRIAL TYPE AND PHASE ²⁷		
E.7.1 Is it:	Human pharmacology (Phase I)	Yes •	
E.7.1.1	First administration to humans	No •	
E.7.1.2	Bioequivalence study	No •	
E.7.1.3	Other:	Yes •	
E.7.1.3.1	If other, please specify:		
	English Safety and tolerability		
E.7.2	Therapeutic exploratory (Phase II)	No •	
E.7.3	Therapeutic confirmatory (Phase III)	No •	
E.7.4	Therapeutic use(Phase IV)	No •	

E.8	DESIGN OF THE TRIAL	
E.8.1	Controlled	No •
	If 'Yes', specify:	
E.8.1.1	Randomised:	No •
E.8.1.2	Open:	Yes •
E.8.1.3	Single blind:	No •
E.8.1.4	Double blind:	No •
E.8.1.5	Parallel group:	No •
E.8.1.6	Cross over:	No •
E.8.1.7	Other:	No •
E.8.1.7.1	If other specify:	
E.8.2	If controlled, specify the comparator:	
E.8.2.1	Other medicinal product(s)	No •
E.8.2.2	Placebo	No •
E.8.2.3	Other	No •
E.8.2.3.1	If 'Yes' to other, specify :	

Single site in the Member State concerned (see also section G): Yes •	
Multiple sites in the Member State concerned(see also section G): No \bullet	
Number of sites anticipated in Member State concerned	
Multiple Member States: No •	
Number of sites anticipated in the EEA:	
5	
5	
	S". If it is not
•	
Initial estimate of the duration of the trial ²⁸ (years, months and days)	
•	
	Multiple sites in the Member State concerned(see also section G): No • Number of sites anticipated in Member State concerned No • Multiple Member States: No • Number of sites anticipated in the EEA: Trial involving sites outside the EEA: Trial being conducted both within and outside the EEA: No • Trial being conducted completely outside of the EEA: No • If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned: If E.8.6.1 or E.8.6.2 are Yes, specify the number of sites anticipated outside of the EEA: No • Trial having an independent data monitoring committee: No • Definition of the end of trial: If it is the last visit of the last subject, please enter "LVLS LVLS provide the definition: English Last Subject Last Visit Initial estimate of the duration of the trial ²⁸ (years, months and days)

F. POPULATION OF TRIAL SUBJECTS

F.1	AGE RANGE			
F.1.1	Are the trial subjects under 18?		No •	
	If 'Yes', specify the estimated number planned in each age range for the wh			
		Approx. No. c	f	
		patients ²⁹		
F.1.1.1	In utero	()	No •	
F.1.1.2	Preterm newborn infants (up to gestational age < 37 weeks)	Ő	No ●	
F.1.1.3	Newborns (0-27 days)	()	No •	
F.1.1.4	Infants and toddlers (28 days - 23 months)	Ő	No •	
F.1.1.5	Children (2-11 years)	()	No •	
F.1.1.6	Adolescents (12-17 years)	Ö	No •	
F.1.2	Adults (18-64 years)	(8)	Yes •	
F.1.3	Elderly (>= 65 years)	()	No •	

F.2	GENDER	
F.2.1	Female	Yes •
F.2.2	Male	Yes •

F.3	GROUP OF TRIAL SUBJECTS	
F.3.1	Healthy volunteers	Yes •
F.3.2	Patients	No •
F.3.3	Specific vulnerable populations	Yes •
F.3.3.1	Women of child bearing potential not using contraception	No •
F.3.3.2	Women of child bearing potential using contraception	Yes •
F.3.3.3	Pregnant women	No •
F.3.3.4	Nursing women	No •
F.3.3.5	Emergency situation	No •
F.3.3.6	Subjects incapable of giving consent personally	No •
F.3.3.6.1	If 'Yes', specify:	
F.3.3.7	Others:	No •
F.3.3.7.1	If 'Yes', specify:	

F.4	PLANNED NUMBER OF SUBJECTS T	O BE INCLUDED:
F.4.1	In the member state	8
F.4.2	For a multinational trial:	
F.4.2.1	In the EEA	
F.4.2.2	In the whole clinical trial	
F.5	PLANS FOR TREATMENT OR CARE A PARTICIPATION IN THE TRIAL. pla	AFTER THE SUBJECT HAS ENDED HIS/HER case specify (free text):

English None

G. CLINICAL TRIAL SITES/INVESTIGATORS IN THE MEMBER STATE CONCERNED BY THIS REQUEST

G.1	CO-ORDINATING INVESTIGATOR (for multicentre trial) and principal investigator (f single centre trial)	
G.1.1	Given name:	Martin
G.1.2	Middle name, if applicable:	
G.1.3	Family name:	Coenen
G.1.4	Qualification (MD)	MD
G.1.5	Professional address:	
G.1.5	Institution name	University Hospital Bonn
G.1.5	Institution department	Phase I-Einheit, Studienzentrale (SZB)
G.1.5.1	Street address	Venusberg-Campus 1
G.1.5.2	Town/city	Bonn
G.1.5.3	Post code	53227
G.1.5.4	Country	Germany
G.1.6	Telephone number:	-
G.1.7	Fax number:	
G.1.8	E-mail:	martin.coenen@ukbonn.de

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)
G.2.1	Given name:
G.2.2	Middle name, if applicable:
G.2.3	Family name:
G.2.4	Qualification (MD)
G.2.5	Professional address:
G.2.5	Institution name
G.2.5	Institution department
G.2.5.1	Street address
G.2.5.2	Town/city
G.2.5.3	Post code
G.2.5.4	Country
G.2.6	Telephone number:
G.2.7	Fax number:
G.2.8	E-mail:

G.3	CENTRAL TECHNICAL FACILIT	IES TO BE USED IN THE CONDUCT OF THE TRIAL
		facility, in which the measurement or assessment of the entralised (repeat as needed for multiple organisations).
G.3.1	Name of organisation:	University Hospital Bonn
G.3.2	Department	Central Laboratory
G.3.3	Name of contact person:	
G.3.3.1	Given name	
G.3.3.2	Middle name	
G.3.3.3	Family name	
G.3.4	Address:	
G.3.4.1	Street address	
G.3.4.2	Town/city	
G.3.4.3	Post code	
G.3.4.4	Country	
G.3.5	Telephone number:	
G.3.6	Fax number:	
G.3.7	E-mail:	
G.3.8	Enter the details of any duties sul	ocontracted to this central technical facility in this trial
G.3.8.1	Routine clinical pathology testing	No •

G.3.8.2	Clinical chemistry	Yes •
G.3.8.3	Clinical haematology	Yes •
G.3.8.4	Clinical microbiology	No •
G.3.8.5	Histopathology	No •
G.3.8.6	Serology/ endocrinology	No •
G.3.8.7	Analytical chemistry	No •
G.3.8.8	ECG analysis/ review	No •
G.3.8.9	Medical image analysis/ review - X-ray, MRI,	No •
	ultrasound, etc.	
G.3.8.10	Primary/ surrogate endpoint test	No •
G.3.8.11	Other Duties subcontracted?	No •
G.3.8.11.1	If 'Yes', specify the other duties	

G.4		IE TRIAL (e.g. Paediatric Networks involved in the
	trial)	
G.4.1	Name of organisation:	
G.4.2	Name of contact person:	
G.4.2.1	Given name	
G.4.2.2	Middle name	
G.4.2.3	Family name	
G.4.3	Address:	
G.4.3.1	Street address	
G.4.3.2	Town/city	
G.4.3.3	Post code	
G.4.3.4	Country	
G.4.4	Telephone number:	
G.4.5	Fax number:	
G.4.6	E-mail:	
G.4.7	Activities carried out by the network:	
G.5	OPCANISATIONS TO WHOM THE	E SPONSOR HAS TRANSFERRED TRIAL RELATED
0.5	DUTIES AND FUNCTIONS	SPONSOR HAS TRANSFERRED TRIAL RELATED
G.5.1		∕ major or all the sponsor's trial Yes •
0.5.1	related duties and functions to a	
	party?	
Reneat as	necessary for multiple organisations:	
Repeat as	necessary for multiple organisations.	
G.5.1.1	Organisation name:	University Hospital Bonn
G.5.1.2	Organisation department	Studienzentrale (SZB)
G.5.1.3	Name of contact person :	
G.5.1.3.1	Given name	
G.5.1.3.2	Middle name	
G.5.1.3.3	Family name	
G.5.1.4	Address:	
G.5.1.4.1	Street address	Venusberg-Campus 1
G.5.1.4.2	Town/city	Bonn
G.5.1.4.3	Post code	53227
G.5.1.4.4	Country	Germany
G.5.1.5	Telephone number:	,
G.5.1.6	Fax number:	
G.5.1.7	E-mail:	studienzentrale-szb@ukbonn.de
G.5.1.8	All tasks of the sponsor	No •
G.5.1.9	Monitoring	No •
G.5.1.10	Regulatory (e.g. preparation of app	
	ethics committee)	
G.5.1.11	Investigator recruitment	No •
G.5.1.12	IVRS ³⁰ – treatment randomisation	No •
G.5.1.12	Data management	No •
G.5.1.14	E-data capture	No •
0.5.1.14	L-uala caplule	

G.5.1.15	SUSAR reporting	Yes ●
G.5.1.16	Quality assurance auditing	No •
G.5.1.17	Statistical analysis	No •
G.5.1.18	Medical writing	No •
G.5.1.19	Other duties subcontracted?	Yes •
G.5.1.19.1	If 'Yes' to other, please specify:	Project Management

H. COMPETENT AUTHORITY / ETHICS COMMITTEE IN THE MEMBER STATE CONCERNED BY THIS REQUEST

H.1 TYPE OF APPLICATION

If this application is addressed to the Competent Authority, please tick the Ethics Committee box and give information on the Ethics committee concerned. If this application is addressed to the Ethics Committee, please tick the Competent Authority box and give the information on the Competent Authority concerned.

H.1.1	Competent Authority	No •	
H.1.2	Ethics Committee	Yes ●	

H.2	INFORMATION ON ETHIC	CS COMMITTEE
H.2.1	Name:	Ethikkommission an der Medizinischen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn
H.2.2	Address	
H.2.2.1	Street address	Venusberg-Campus 1
H.2.2.2	Town/city	Bonn
H.2.2.3	Post code	53227
H.2.2.4	Country	Germany
H.2.3	Date of submission:	2021-10-04
H.3	OPINION	
H.3.1	To be requested	No ●
H.3.2	Pending	Yes •
H.3.3	Given	No ●
	If 'Given', specify:	
11 2 2 1	Data of oninions	

H.3.3.1	Date of opinion:	
H.3.3.2	Opinion favourable	No ●
H.3.3.3	Opinion not favourable	No ●
	If not favourable, give:	
H.3.3.3.1	The reasons	
нзззр	The eventual anticipated dat	of resubmission.

I. SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

I.1	I hereby confirm that /confirm on behalf of the sponsor (delete which is not applicable) that:
	 the information provided is complete;
	 the attached documents contain an accurate account of the information available;
	 the clinical trial will be conducted in accordance with the protocol; and
	 the clinical trial will be conducted, and SUSARs and result-related information will be
	reported, in accordance with the applicable legislation.
I.2	APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY (as stated in section C.1):
	APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY (as stated in section C.1): Date:
I.2 I.2.1 I.2.2	
I.2.1	Date:
I.2.2	Date: Signature ³¹ :

1.5	APPLICANT OF THE REQUEST FOR THE ETHICS C
I.3.1	Date:
I.3.2	Signature ³² :
I.3.3	Print name:

ENDNOTES

¹ Any translation of the protocol should be assigned the same date and version as those in the original document.

² International Standard Randomised Controlled Trial Number. Sponsors may wish to use an International Standardised Random Controlled Trial Number (ISRCTN) to identify their trial in addition to the EudraCT number; for instance if their trial is part of a multinational trial with sites outside the Community. They can obtain the number and guidance from the Current Controlled Trials website http://www.controlled-trials.com/isrctn to which there is a link from the EudraCT database website http://eudract.ema.europa.eu.

When available they should provide it in Section A.6 of the application form. ³ US National Clinical Trial (NCT) Numbers required on the FDA clinical trial application form.

⁴ For a resubmission following previous withdrawal of an application or unfavourable opinion of an ethics committee, or previous withdrawal of an application or refusal of a request by the competent authority, enter a letter in the sequence, A for first resubmission, B for second, C for third et seq.

⁵ In accordance with Article 19 of Directive 2001/20/EC.

⁶ The contact point should give functional information rather than details of one "person", in order to avoid the need for update and maintenance of these contact details.

⁷ This requires a EudraLink account. (See https://eudract.ema.europa.eu/document.html for details)
 ⁸ According to national legislation.

⁹ Available from the Summary of Product Characteristics (SmPC)

¹⁰ According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000): <u>http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm</u>

¹¹ Committee for Medicinal Products for Human Use of the European Medicines Agency

¹² To be provided only when there is No trade name. This is the name routinely used by a sponsor to identify the IMP in the CT documentation (protocol, IB...).

¹³ To be provided only when there is No trade name. This is a code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices.

¹⁴ Available from the Summary of Product Characteristics (SmPC).

¹⁵ Chemical Abstracts Service.

¹⁶ Complete also section D.4 Cell therapy as defined in Annex 1 part IV of Directive 2001/83/EC as amended.

¹⁷ Complete also section D.5 Gene Therapy as defined in Annex 1 part IV of Directive 2001/83/EC as amended.

 18 Complete also section D.6 - Tissue Engineered Product as defined in Article 2(1)(b) of

Regulation1394/2007/EC.

¹⁹ Complete also section D.7

²⁰ The mode of action should briefly describe the chemical, biochemical, immunological or biological means the IMP uses to effect its pharmaceutical action.

²¹ Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/2007 19 July 2007

²² In accordance with paragraph 38 of Annex 13 of Volume 4 of the Rules Governing Medical Products in the European Union.

²³ In the case of healthy volunteer trials, the intended indication for the product under development should be provided.

²⁴ Applicants are encouraged to provide the MedDRA lower level term if applicable and classification code. These can be accessed from the EMEA EudraCT website (<u>http://eudract.ema.europa.eu/</u>).

²⁵ Points to consider on the calculation and reporting of the prevalence of a condition for Orphan drug designation: COM/436/01 (<u>http://www.ema.europa.eu/htms/human/orphans/intro.htm</u>).

²⁶ The protocol will usually identify a single primary end point but there may be a co-primary end point in some cases and/or a number of secondary end points.

²⁷ The descriptions of the trial types provided are those recommended in preference to Phases. See page 5 of Community guideline CPMP/ICH/291/95. The development of a new indication after initial approval of a medicine should be considered as a new development plan.

²⁸ From the first inclusion until the last visit of the last subject.

²⁹ These numbers will be initial estimates. Applicants will not be required to update this information nor do they constitute an authorisation or restriction on the inclusion of these numbers of patients in the trial. The numbers of subjects whose inclusion is authorised are those set out in the authorised version of the protocol, or subsequent authorised amendments.

³⁰ Interactive Voice Response System: commonly used for randomisation of treatment and controlling the shipment of stock of product.

³¹ On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.

³² On an application to the Ethics Committee only, the applicant to the Ethics Committee needs to sign.

REQUEST FOR AUTHORISATION OF A CLINICAL TRIAL ON A MEDICINAL PRODUCT FOR HUMAN USE TO THE COMPETENT AUTHORITIES AND FOR OPINION OF THE ETHICS COMMITTEES IN THE COMMUNITY

To be filled in by the applicant

The questions in this form for the request for authorisation from the Competent Authority are also relevant for the opinion from an Ethics Committee (it represents module 1 of the form for applying to an ethics committee) and can be used as part of that application. Please indicate the relevant purpose in a box below.

Yes •

No •

REQUEST FOR AUTHORISATION TO THE COMPETENT AUTHORITY: REQUEST FOR OPINION OF THE ETHICS COMMITTEE:

A. TRIAL IDENTIFICATION

A.1 A.2	EudraCT number:	hich the submission is being made	Spain - AEMPS 2022-003111-28
A.3	Full title of the trial	-	
	English	Mechanism-based drug REpu Preserved Ejection Fraction (rPOsing in a subtype of Heart Failure with REPO-HFPEF)
	Spanish		ógico basado en el mecanismo en un subtipo fracción de eyección conservada''
A.3.1	Title of the trial for English		e. non-technical, language: ile of the combination of vericiguat, L- ts with a subtype of heart failure with
	Spanish		de seguridad de la combinación de vericiguat, tes con un subtipo de insuficiencia cardiaca servada.
A.3.2	Name or abbreviate	ed title of the trial where available:	
A.4		code number, version and date1:	
A.4.1	Sponsor's protocol		REPO-HFpEF-II
A.4.2	Sponsor's protocol		3.0
A.4.3	Sponsor's protocol		2023-03-13
A.5			SRCTN ² , US NCT Number ³) if available
A.5.1	ISRCTN number:		
A.5.2	US NCT number:		
A.5.3	WHO Universal Tria	l Number (UTN):	
A.5.4	Other Identifier:		
A.6	Is this a resubmissi	ion?	No •
	•		ubmission
A.7	•	an agreed Paediatric Investigation	
A.8	EMA Decision numb	per of Paediatric Investigation Plan	

B. IDENTIFICATION OF THE SPONSOR RESPONSIBLE FOR THE REQUEST

B.1	SPONSOR	
B.1.1	Name of organisation:	Hospital Clínico Universitario de Valencia
B.1.2	Name of the person to contact:	
B.1.2.1	Given name	Julio
B.1.2.2	Middle name	
B.1.2.3	Family name	Núñez Villota
B.1.3	Address:	
B.1.3.1	Street address	Avda. Menédez Pelayo 4 acc
B.1.3.2	Town/city	Valencia
B.1.3.3	Post code	46010
B.1.3.4	Country	Spain
B.1.4	Telephone number:	0034 96 1973536
B.1.5	Fax number:	0034 96 1973540
B.1.6	E-mail:	gestioncientifica@incliva.es
		-
B.2	LEGAL REPRESENTATIVE ⁵ OF	THE SPONSOR IN THE COMMUNITY FOR THE PURPOSE OF
	THIS TRIAL (if different from th	e sponsor)
B.2.1	Name of organisation:	

B.2.1	Name of organisation:
B.2.2	Name of person to contact:
B.2.2.1	Given name
B.2.2.2	Middle name
B.2.2.3	Family name
B.2.3	Address:
B.2.3.1	Street address
B.2.3.2	Town/city
B.2.3.3	Post code
B.2.3.4	Country
B.2.4	Telephone number:
B.2.5	Fax number:
B.2.6	E-mail:

B.3	STATUS OF THE SPONS	OR:
B.3.1	Commercial:	No •
B.3.2	Non commercial:	Yes •
P /	Source(s) of Monetary	or Material Support for the clinical trial (repeat as percessary);

B.4	Source(s) of Monetary or	Material Support for the clinical trial (repeat as necessary):
B.4.1	Name of organisation:	University of Maastricht
B.4.2	Country:	Netherlands

B.5	Contact point ⁶ designated by the spon	sor for further information on the trial
B.5.1	Name of organisation:	Instituto de Investigación Sanitaria INCLIVA
B.5.2	Functional name of contact point (e.g. "Clinical Trial Information Desk"):	Sub-Directora Científica
B.5.3	Address:	
B.5.3.1	Street address	Avda. Menédez Pelayo 4 acc
B.5.3.2	Town/city	Valencia
B.5.3.3	Post code	46010
B.5.3.4	Country	Spain
B.5.4	Telephone number:	0034 96 1973536
B.5.5	Fax number:	0034 96 1973540
B.5.6	E-mail: (use a functional e-mail address rather than a personal one)	gestioncientifica@incliva.es

C. APPLICANT IDENTIFICATION, (please tick the appropriate box)

C.1	REQUEST FOR THE COMPE	TENT AUTHORITY
C.1.1	Sponsor	
C.1.2	Legal representative of the s	ponsor
C.1.3	Person or organisation autho	rised by the sponsor to make the application Yes •
C.1.4	Complete the details of the a	pplicant below even if they are provided elsewhere on the form:
C.1.4.1	Name of Organisation:	Instituto de Investigación Sanitaria INCLIVA
C.1.4.2	Name of contact person:	
C.1.4.2.1	Given name	Ana
C.1.4.2.2	Middle name	
C.1.4.2.3	Family name	Portolés Monzón
C.1.4.3	Address:	
C.1.4.3.1	Street address	Avd. Menendez Pelayo 4 acc
C.1.4.3.2	Town/city	Valencia
C.1.4.3.3	Post code	
C.1.4.3.4	Country	Spain
C.1.4.4	Telephone number:	0034 96 1973536
C.1.4.5	Fax number:	0034 96 1973540
C.1.4.6	E-mail:	gestioncientifica@incliva.es
C.1.5	Request to receive a copy of	CTA data as XML:
C.1.5.1	Do you want a copy of the C	TA form data saved on EudraCT as an XML Yes •
	file?	
C.1.5.1.1	If Yes provide the e-mail add	lress(es) to which it should be sent (up to 5 addresses):
	uicec@incliva.es	
C.1.5.1.2	Do you want to receive this v	via password protected link(s)? No \bullet
If you answ		he xml file will be transmitted by less secure e-mail link(s)

D. INFORMATION ON EACH IMP

Information on each 'bulk product' before trial-specific operations (blinding, trial specific packaging and labelling) should be provided in this section for each investigational medicinal product (IMP) being tested including each comparator and each placebo, if applicable. **For placebo go directly to D.8**. If the trial is performed with several products use extra pages and give each product a sequential number in D.1.1. If the product is a combination product, information should be given for each active substance.

D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):

D.1.1	This refers to the IMP number:	PR1
D.1.2	IMP being tested	Yes •
D.1.3	IMP used as a comparator	No •

D.2 STATUS OF THE IMP

D.2.1 Has the IMP to be used in the trial a marketing authorisation? Yes • If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2. If 'Yes', specify the product to be used in the clinical trial: D.2.1.1 Verguvo D.2.1.1.1 Trade name EV Product Code (where applicable) D.2.1.1.1.1 Name of the Marketing Authorisation Holder: D.2.1.1.2 **Bayer AG** D.2.1.1.3 Marketing Authorisation number (if Marketing Authorisation granted by a Member State): D.2.1.1.4 Is the IMP modified in relation to its Marketing Authorisation? No • D.2.1.1.4.1 If 'Yes', please specify: The country that granted the Marketing Authorisation D.2.1.2 Spain D.2.1.2.1 Is this the Member State concerned with this application? Yes •

D.2.2	Situations where an IMP to be used in the CT has a Marketing Authorisation in the Member State concerned, but the protocol allows that any brand of the IMP with a Marketing Authorisation in		
	that Member State be administered to the trial subjects a the IMP(s) in advance of the trial start	and it is not possible to clearly identify	
D.2.2.1	In the protocol, is treatment defined only by active substance?	No •	
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9		
D.2.2.2	In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS?	No •	
D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9		
D.2.2.3	The products to be administered as IMPs are defined as belonging to an ATC group ⁹	Yes •	
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised of the level that can be defined) in D.3.3	codes in the ATC code field (level 3 or	
D.2.2.4	Other:	No •	
D.2.2.4.1	If 'Yes', please specify:		

D.2.3	IMPD submitted:	
D.2.3.1	Full IMPD:	No •
D.2.3.2	Simplified IMPD:	No •
D.2.3.3	Summary of product characteristics (SmPC) only:	Yes •
D.2.4	Has the use of the IMP been previously authorised in a	No •

D.2.4.1	clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States:	
D.2.5	Has the IMP been designated in this indication as an orphan drug in the Community?	No •
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :	
D.2.6	Has the IMP been the subject of scientific advice related to this clinical trial?	No •
D.2.6.1 D.2.6.1.1	If 'Yes' to D.2.6, please indicate source of advice and pro CHMP ¹¹ ?	ovide a copy in the CTA request: No \bullet
D.2.6.1.2		No •

D.3	DESCRIPTION OF THE IMP	
D.3.1	Product name where applicable ¹² :	
D.3.2	Product code where applicable ¹³ :	
D.3.3	ATC codes, if officially registered ¹⁴ :	C01
D.3.4	Pharmaceutical form (use standard terms):	Tablet
D.3.4.1	Is this a specific paediatric formulation?	No •
D.3.5	Maximum duration of treatment of a subject accordin	g to the protocol:
	84 days	
D.3.6	Dose allowed:	
D.3.6.1	For first trial only:	
	Specify per day or total	Total •
	Specify total dose (number and unit):	
	Route of administration (relevant to the first dose):	
D.3.6.2	For all trials	
	Specify per day or total	Total •
	Specify total dose (number and unit):	752.5 mg milligram(s)
	Route of administration (relevant to the maximum dose):	Oral use
D.3.7	Routes of administration (use standard terms):	Oral use

D.3.8	Name of each active substance (INN or proposed INN if available):
D.3.9	Other available name for each active substance (provide all available):
D.3.9.1	CAS ¹⁵ number
D.3.9.2	Current sponsor code
D.3.9.3	Other descriptive name
D.3.9.4	EV Substance code
D.3.9.5	Full Molecular formula
D.3.9.6	Chemical/biological description of the Active Substance
D.3.10	Strength (specify all strengths to be used):
D.3.10.1	Concentration unit:
D.3.10.2	Concentration type ("exact number", "range", "more than" or "up to"):
D.3.10.3	Concentration (number).

D.3.11	Type of IMP	
Does the IMP	contain an active substance:	
D.3.11.1	Of chemical origin?	Yes •
D.3.11.2	Of biological / biotechnological origin (other than Advanced Therapy IMP (ATIMP)?	No •
Is this a:		
D.3.11.3	Advanced Therapy IMP (ATIMP)?	No •
D.3.11.3.1	Somatic cell therapy medicinal product ¹⁶ ?	No •
D.3.11.3.2	Gene therapy medicinal product ¹⁷ ?	No •

D.3.11.3.3	Tissue Engineered Product ¹⁸ ?	No •
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical	No •
	device ¹⁹)?	
D.3.11.3.5	Has the Committee on Advanced Therapies issued a	No •
	classification for this product?	
D.3.11.3.5.1	If 'Yes' please provide that classification and its reference	ce number:
D.3.11.4	Combination product that includes a device, but does	No •
	not involve an Advanced Therapy?	
D.3.11.5	Radiopharmaceutical medicinal product?	No •
D.3.11.6	Immunological medicinal product (such as vaccine,	No •
	allergen, immune serum)?	
D.3.11.7	Plasma derived medicinal product?	No •
D.3.11.8	Extractive medicinal product?	No •
D.3.11.9	Recombinant medicinal product?	No •
D.3.11.10	Medicinal product containing genetically modified organisms?	No •
D.3.11.10.1	Has the authorisation for contained use or release been granted?	No •
D.3.11.10.2	Is it pending?	No •
D.3.11.11	Herbal medicinal product?	No •
D.3.11.12	Homeopathic medicinal product?	No •
D.3.11.12	Another type of medicinal product?	No •
D.3.11.13.1	If 'another type of medicinal product' specify the type of	
0.5.11.15.1	in another type of medicinal product specify the type t	
D.3.12	Mode of action (<i>free text</i> ²⁰)	
D.3.13	Is it an IMP to be used in a first-in-human clinical trial?	No •
D.3.13.1	If 'Yes', are there risk factors identified, according to the	e guidance FIH? ²¹
		5

D.4 SOMATIC CELL THERAPY INVESTIGATIONAL MEDICINAL PRODUCT (NO GENETIC **MODIFICATION)** D.4.1 Origin of cells D.4.1.1 Autologous No • D.4.1.2 Allogeneic No • D.4.1.3 Xenogeneic No • D.4.1.3.1 If 'Yes', specify the species of origin: D.4.2 Type of cells D.4.2.1 Stem cells No • D.4.2.2 Differentiated cells No • D.4.2.2.1 If 'Yes', specify the type (e.g. keratinocytes, fibroblasts, chondrocytes...): D.4.2.3 Others: No • D.4.2.3.1 If others, specify:

D.5	GENE THERAPY INVESTIGATIONAL MEDICINAL PRO	DUCTS	
D.5.1	Gene(s) of interest:		
D.5.2	In vivo gene therapy:	No •	
D.5.3	Ex vivo gene therapy:	No •	
D.5.4	Type of gene transfer product		
D.5.4.1	Nucleic acid (e.g. plasmid):	No •	
	If 'Yes', specify if:		
D.5.4.1.1	Naked:	No •	
D.5.4.1.2	Complexed	No •	
D.5.4.2	Viral vector:	No •	
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus, AAV,:		
D.5.4.3	Others	No •	

D.6	TISSUE ENGINEERED PRODUCT		
D.5.5.4	Specify type of cells (hematopoietic stem cells):		
D.5.5.3.1	If 'Yes', specify the species of origin:		
D.5.5.3	Xenogeneic:	No •	
D.5.5.2	Allogeneic:	No •	
D.5.5.1	Autologous:	No •	
If 'Yes', spee	cify the origin of the cells:		
D.5.5	Genetically modified somatic cells:	No •	
D.5.4.3.1	If others, specify:		

The indication which determines that this is a Tissue Engineered Product as opposed to a Cell Therapy product is given in section E.1.1.

2		
D.6.1	Origin of cells	
D.6.1.1	Autologous	No •
D.6.1.2	Allogeneic	No •
D.6.1.3	Xenogeneic	No •
D.6.1.3.1	If 'Yes', specify the species of origin:	
D.6.2	Type of cells	
D.6.2.1	Stem cells	No •
D.6.2.2	Differentiated cells	No •
D.6.2.2.1	If 'Yes', specify the type of cells(e.g. l	<pre>keratinocytes, fibroblasts, chondrocytes,):</pre>
D.6.2.3	Others:	No •
D.6.2.3.1	If others, specify:	

D.7	PRODUCTS CONTAINING DEVICES (i.e. MEDI	CAL DEVICES, SCAFFOLDS ETC.)
D.7.1	Give a brief description of the device:	
D.7.2	What is the name of the device?	
D.7.3	Is the device implantable?	No •
D.7.4	Does this product contain:	
D.7.4.1	A medical device?	No •
D.7.4.1.1	Does this medical device have a CE mark?	No •
D.7.4.1.1.1	The notified body is:	
D.7.4.2	Bio-materials?	No •
D.7.4.3	Scaffolds?	No •
D.7.4.4	Matrices?	No •
D.7.4.5	Other?	No •
D.7.4.5.1	If other, specify:	

D.1	IMP IDENTIFICATION	
	which of the following is described below, then repeat as n in the trial (assign numbers from 1-n):	necessary for each of the numbered IMPs to
D.1.1	This refers to the IMP number:	PR2
D.1.2	IMP being tested	Yes •
D.1.3	IMP used as a comparator	No •
	·	
D.2	STATUS OF THE IMP	

D.2.1 Has the IMP to be used in the trial a marketing authorisation? Yes • If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2.

1		
D.2.1.1	If 'Yes', specify the product to be used in the clinical tria	al•
D.2.1.1.1	Trade name Stimol	
D.2.1.1.1.1	EV Product Code (where applicable)	
D.2.1.1.2	Name of the Marketing Authorisation Holder:	
D.2.1.1.3	Marketing Authorisation number (if Marketing	
0.2.1.1.5	Authorisation granted by a Member State):	
D.2.1.1.4	Is the IMP modified in relation to its Marketing Authorisa	ation? No •
D.2.1.1.4.1	If 'Yes', please specify:	
Diction		
D.2.1.2	The country that granted the Marketing Authorisation	Spain
D.2.1.2.1	Is this the Member State concerned with this application	n? Yes ●
D.2.2	Situations where an IMP to be used in the CT has a Mar	
	concerned, but the protocol allows that any brand of the	
	that Member State be administered to the trial subjects	and it is not possible to clearly identify
D D D 1	the IMP(s) in advance of the trial start	N -
D.2.2.1	In the protocol, is treatment defined only by active	No •
	substance?	
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9	No
D.2.2.2	In the protocol, do treatment regimens allow different	No •
	combinations of marketed products used according to	
	local clinical practice at some or all investigator sites in	
1	the MS?	
D.2.2.2.1 D.2.2.3	If 'Yes', give active substance in D.3.8 or D.3.9 The products to be administered as IMPs are defined as	Yes •
D.2.2.3	belonging to an ATC group ⁹	res •
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised	codes in the ATC code field (lovel 2 or
D.2.2.3.1	the level that can be defined) in D.3.3	codes in the ATC code held (level 5 of
D.2.2.4	Other:	No •
0.2.2.4		
D2241	If 'Yes' nlease specify:	
D.2.2.4.1	If 'Yes', please specify:	
D.2.3	IMPD submitted:	
D.2.3 D.2.3.1	IMPD submitted: Full IMPD:	No •
D.2.3 D.2.3.1 D.2.3.2	IMPD submitted: Full IMPD: Simplified IMPD:	No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only:	No ● Yes ●
D.2.3 D.2.3.1 D.2.3.2	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a	No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the	No ● Yes ●
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community?	No ● Yes ●
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4.1	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States:	No • Yes • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an	No ● Yes ●
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.4.1 D.2.5	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community?	No • Yes • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4.1	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an	No • Yes • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.4.1 D.2.5	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community?	No • Yes • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.4 D.2.5 D.2.5.1	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ :	No • Yes • No • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.4.1 D.2.5	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community?	No • Yes • No • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.4 D.2.5 D.2.5.1	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial?	No • Yes • No • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.4 D.2.5 D.2.5.1 D.2.5.1	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related	No • Yes • No • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.4 D.2.5 D.2.5 D.2.5.1 D.2.6 D.2.6.1	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial? If 'Yes' to D.2.6, please indicate source of advice and pr	No • Yes • No • No • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.4 D.2.5 D.2.5.1 D.2.5.1 D.2.6 D.2.6.1 D.2.6.1.1	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial? If 'Yes' to D.2.6, please indicate source of advice and pr CHMP ¹¹ ?	No • Yes • No • No • No • ovide a copy in the CTA request: No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.5 D.2.5.1 D.2.5.1 D.2.6 D.2.6.1 D.2.6.1.1 D.2.6.1.2	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial? If 'Yes' to D.2.6, please indicate source of advice and pr CHMP ¹¹ ? National Competent Authority?	No • Yes • No • No • No • ovide a copy in the CTA request: No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.5 D.2.5.1 D.2.6 D.2.6.1 D.2.6.1.1 D.2.6.1.2 D.3	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial? If 'Yes' to D.2.6, please indicate source of advice and pr CHMP ¹¹ ? National Competent Authority? DESCRIPTION OF THE IMP	No • Yes • No • No • No • ovide a copy in the CTA request: No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.5 D.2.5.1 D.2.6 D.2.6.1 D.2.6.1.1 D.2.6.1.2 D.3.1	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial? If 'Yes' to D.2.6, please indicate source of advice and pr CHMP ¹¹ ? National Competent Authority? Product name where applicable ¹² :	No • Yes • No • No • No • ovide a copy in the CTA request: No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.5 D.2.5.1 D.2.6.1 D.2.6.1.1 D.2.6.1.1 D.2.6.1.2 D.3.1 D.3.1 D.3.2	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial? If 'Yes' to D.2.6, please indicate source of advice and pr CHMP ¹¹ ? National Competent Authority? DESCRIPTION OF THE IMP Product name where applicable ¹² : Product code where applicable ¹³ :	No • Yes • No • No • No • No • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.5 D.2.5.1 D.2.6.1 D.2.6.1.1 D.2.6.1.1 D.2.6.1.2 D.3.1 D.3.1 D.3.2 D.3.3	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial? If 'Yes' to D.2.6, please indicate source of advice and pr CHMP ¹¹ ? National Competent Authority? DESCRIPTION OF THE IMP Product name where applicable ¹² : Product code where applicable ¹³ : ATC codes, if officially registered ¹⁴ :	No • Yes • No • No • No • No • No • No • No • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.5 D.2.5.1 D.2.6 D.2.6.1 D.2.6.1.1 D.2.6.1.2 D.2.6.1.2 D.3.1 D.3.1 D.3.2 D.3.3 D.3.4	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial? If 'Yes' to D.2.6, please indicate source of advice and pr CHMP ¹¹ ? National Competent Authority? DESCRIPTION OF THE IMP Product name where applicable ¹² : Product code where applicable ¹³ : ATC codes, if officially registered ¹⁴ : Pharmaceutical form (use standard terms):	No • Yes • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.5 D.2.5.1 D.2.6.1 D.2.6.1.1 D.2.6.1.1 D.2.6.1.2 D.3.1 D.3.1 D.3.2 D.3.3 D.3.4 D.3.4,1	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial? If 'Yes' to D.2.6, please indicate source of advice and pr CHMP ¹¹ ? National Competent Authority? DESCRIPTION OF THE IMP Product name where applicable ¹² : Product code where applicable ¹³ : ATC codes, if officially registered ¹⁴ : Pharmaceutical form (use standard terms): Is this a specific paediatric formulation?	No • Yes • No •
D.2.3 D.2.3.1 D.2.3.2 D.2.3.3 D.2.4 D.2.4 D.2.5 D.2.5.1 D.2.6 D.2.6.1 D.2.6.1.1 D.2.6.1.1 D.2.6.1.2 D.3.1 D.3.1 D.3.2 D.3.3 D.3.4	IMPD submitted: Full IMPD: Simplified IMPD: Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a clinical trial conducted by the sponsor in the Community? If 'Yes' specify which Member States: Has the IMP been designated in this indication as an orphan drug in the Community? If 'Yes', give the orphan drug designation number ¹⁰ : Has the IMP been the subject of scientific advice related to this clinical trial? If 'Yes' to D.2.6, please indicate source of advice and pr CHMP ¹¹ ? National Competent Authority? DESCRIPTION OF THE IMP Product name where applicable ¹² : Product code where applicable ¹³ : ATC codes, if officially registered ¹⁴ : Pharmaceutical form (use standard terms):	No • Yes • No •

D.3.6 D.3.6.1	Dose allowed: For first trial only: Specify per day or total Specify total dose (number and unit): Route of administration (relevant to the first dose):	Total •
D.3.6.2	For all trials	
	Specify per day or total	Total •
	Specify total dose (number and unit):	252 g gram(s)
	Route of administration (relevant to the maximum dose):	Oral use
D.3.7	Routes of administration (use standard terms):	Oral use

D.3.8	Name of each active substance (INN or proposed INN if available):
D.3.9	Other available name for each active substance (provide all available):
D.3.9.1	CAS ¹⁵ number
D.3.9.2	Current sponsor code
D.3.9.3	Other descriptive name
D.3.9.4	EV Substance code
D.3.9.5	Full Molecular formula
D.3.9.6	Chemical/biological description of the Active Substance
D.3.10	Strength (specify all strengths to be used):
D.3.10.1	Concentration unit:
D.3.10.2	Concentration type ("exact number", "range", "more than" or "up to"):
D.3.10.3	Concentration (number).

D.3.11	Type of IMP	
Does the IMP D.3.11.1 D.3.11.2	contain an active substance: Of chemical origin? Of biological / biotechnological origin (other than	Yes ∙ No ∙
Is this a:	Advanced Therapy IMP (ATIMP)?	
D.3.11.3 D.3.11.3.1 D.3.11.3.2 D.3.11.3.3	Advanced Therapy IMP (ATIMP)? Somatic cell therapy medicinal product ¹⁶ ? Gene therapy medicinal product ¹⁷ ? Tissue Engineered Product ¹⁸ ?	No • No • No • No •
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device ¹⁹)?	No •
D.3.11.3.5	Has the Committee on Advanced Therapies issued a classification for this product? If 'Yes' please provide that classification and its reference	No •
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy?	No •
D.3.11.5 D.3.11.6	Radiopharmaceutical medicinal product? Immunological medicinal product (such as vaccine, allergen, immune serum)?	No ● No ●
D.3.11.7 D.3.11.8 D.3.11.9	Plasma derived medicinal product? Extractive medicinal product? Recombinant medicinal product?	No ● No ● No ●
D.3.11.10 D.3.11.10.1	Medicinal product containing genetically modified organisms? Has the authorisation for contained use or release	No •
D.3.11.10.2 D.3.11.11 D.3.11.12 D.3.11.13	been granted? Is it pending? Herbal medicinal product? Homeopathic medicinal product? Another type of medicinal product?	No ● No ● No ● No ●
D.3.11.13	If 'another type of medicinal product' specify the type of	

- D.3.12 Mode of action (*free text*²⁰)
- D.3.13
- Is it an IMP to be used in a first-in-human clinical trial? No If 'Yes', are there risk factors identified, according to the guidance FIH?²¹ D.3.13.1

D.4	SOMATIC CELL THERAPY INVESTIGAT MODIFICATION)	IONAL MEDICINAL PRODUCT (NO GENETIC
D.4.1	Origin of cells	
D.4.1.1	Autologous	No •
D.4.1.2	Allogeneic	No •
D.4.1.3	Xenogeneic	No •
D.4.1.3.1	If 'Yes', specify the species of origin:	
D.4.2	Type of cells	
D.4.2.1	Stem cells	No •
D.4.2.2	Differentiated cells	No •
D.4.2.2.1	If 'Yes', specify the type (e.g. keratinocyte	es, fibroblasts, chondrocytes):
D.4.2.3	Others:	No ●
D.4.2.3.1	If others, specify:	

D.5	GENE THERAPY INVESTIGATIONAL MEDIC	INAL PRODUCTS	
D.5.1	Gene(s) of interest:		
D.5.2	In vivo gene therapy:	No •	
D.5.3	Ex vivo gene therapy:	No •	
D.5.4	Type of gene transfer product		
D.5.4.1	Nucleic acid (e.g. plasmid):	No •	
D.5.4.1.1	If 'Yes', specify if: Naked:	No •	
D.5.4.1.2	Complexed	No •	
D.5.4.2	Viral vector:	No •	
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovirus	s, AAV,:	
D.5.4.3	Others	No •	
D.5.4.3.1	If others, specify:		
D.5.5	Genetically modified somatic cells:	No •	
If 'Yes', spe	cify the origin of the cells:		
D.5.5.1	Autologous:	No •	
D.5.5.2	Allogeneic:	No •	
D.5.5.3	Xenogeneic:	No •	
D.5.5.3.1	If 'Yes', specify the species of origin:		
D.5.5.4	Specify type of cells (hematopoietic stem cells.	.):	

	TISSUE ENGINEERED PRODUCT on which determines that this is a Tissue Engineer ection E.1.1.	ed Product as opposed to a Cell Therapy p	roduct
D.6.1	Origin of cells		
D.6.1.1	Autologous	No •	
D.6.1.2	Allogeneic	No •	
D.6.1.3	Xenogeneic	No •	
D.6.1.3.1	If 'Yes', specify the species of origin:		
D.6.2	Type of cells		
D.6.2.1	Stem cells	No •	
D.6.2.2	Differentiated cells	No •	

D.6.2.2.1 If 'Yes', specify the type of cells(e.g. keratinocytes, fibroblasts, chondrocytes, ...):

D.6.2.3 Others:

D.6.2.3.1 If others, specify:

D.7 PRODUCTS CONTAINING DEVICES (i.e. MEDICAL DEVICES, SCAFFOLDS ETC.) D.7.1 Give a brief description of the device: D.7.2 What is the name of the device? D.7.3 Is the device implantable? No • D.7.4 Does this product contain: D.7.4.1 A medical device? No • Does this medical device have a CE mark? D.7.4.1.1 No • The notified body is: D.7.4.1.1.1 D.7.4.2 **Bio-materials?** No • Scaffolds? D.7.4.3 No • D.7.4.4 Matrices? No • D.7.4.5 No • Other? D.7.4.5.1 If other, specify:

No •

D.1 IMP IDENTIFICATION

Indicate which of the following is described below, then repeat as necessary for each of the numbered IMPs to be used in the trial (assign numbers from 1-n):

D.1.1	This refers to the IMP number:	PR3
D.1.2	IMP being tested	Yes •
D.1.3	IMP used as a comparator	No •

D.2 STATUS OF THE IMP

D.2.1 Has the IMP to be used in the trial a marketing authorisation? Yes • If the IMP has a marketing authorisation in the Member State concerned by this application, but the trade name and marketing authorisation holder are not fixed in the protocol, go to section D.2.2. If 'Yes', specify the product to be used in the clinical trial: D.2.1.1 Acfol D.2.1.1.1 Trade name D.2.1.1.1.1 EV Product Code (where applicable) D.2.1.1.2 Name of the Marketing Authorisation Holder: D.2.1.1.3 Marketing Authorisation number (if Marketing Authorisation granted by a Member State): D.2.1.1.4 Is the IMP modified in relation to its Marketing Authorisation? No •

D.2.1.1.4.1 If 'Yes', please specify:

D.2.1.2The country that granted the Marketing AuthorisationSpainD.2.1.2.1Is this the Member State concerned with this application?Yes •

D.2.2	Situations where an IMP to be used in the CT has a Marke concerned, but the protocol allows that any brand of the I that Member State be administered to the trial subjects ar the IMP(s) in advance of the trial start	MP with a Marketing Authorisation in
D.2.2.1	In the protocol, is treatment defined only by active substance?	No •
D.2.2.1.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.2	In the protocol, do treatment regimens allow different combinations of marketed products used according to local clinical practice at some or all investigator sites in the MS?	No •

D.2.2.2.1	If 'Yes', give active substance in D.3.8 or D.3.9	
D.2.2.3	The products to be administered as IMPs are defined as	Yes •
	belonging to an ATC group ⁹	
D.2.2.3.1	If 'Yes', give the ATC group of the applicable authorised	codes in the ATC code field (level 3 or
D D D D D D D D D D	the level that can be defined) in D.3.3	NI -
D.2.2.4 D.2.2.4.1	Other: If 'Yes', please specify:	No •
D.2.2.4.1	If tes, please specify.	
<u> </u>		
D.2.3	IMPD submitted:	No
D.2.3.1 D.2.3.2	Full IMPD: Simplified IMPD:	No ● No ●
D.2.3.2 D.2.3.3		Yes •
D.2.3.3 D.2.4	Summary of product characteristics (SmPC) only: Has the use of the IMP been previously authorised in a	
D.2.4	clinical trial conducted by the sponsor in the	NO •
	Community?	
D.2.4.1	If 'Yes' specify which Member States:	
D.2.5	Has the IMP been designated in this indication as an	No •
0.2.3	orphan drug in the Community?	
D.2.5.1	If 'Yes', give the orphan drug designation number ¹⁰ :	
D.2.6	Has the IMP been the subject of scientific advice related	No •
	to this clinical trial?	
D.2.6.1	If 'Yes' to D.2.6, please indicate source of advice and pr	
D.2.6.1.1	CHMP ¹¹ ?	
D.2.6.1.2	National Competent Authority?	No •
D 2		
D.3	DESCRIPTION OF THE IMP	
D.3.1	Product name where applicable ¹² :	
D.3.2	Product code where applicable ¹³ :	D00DD01
D.3.3	ATC codes, if officially registered ¹⁴ :	B03BB01
D.3.4	Pharmaceutical form (use standard terms):	Tablet No •
D.3.4.1 D.3.5	Is this a specific paediatric formulation? Maximum duration of treatment of a subject according	-
0.0.0	84 days	
D.3.6	Dose allowed:	
D.3.6.1	For first trial only:	
0.0.0.1	Specify per day or total	Total •
	Specify total dose (number and unit):	
	Route of administration (relevant to the first dose):	
D.3.6.2	For all trials	
	Specify per day or total	Total •
	Specify total dose (number and unit):	420 mg milligram(s)
	Route of administration (relevant to the maximum	Oral use
	dose):	
D.3.7	Routes of administration (use standard terms):	Oral use
-		
D.3.8	Name of each active substance (INN or proposed INN i	f available):
D.3.9	Other available name for each active substance (provi	
D.3.9.1	CAS ¹⁵ number	,
D.3.9.2	Current sponsor code	
D.3.9.3	Other descriptive name	
D.3.9.4	EV Substance code	
D.3.9.5	Full Molecular formula	
D.3.9.6	Chemical/biological description of the Active Substance	2
D.3.10	Strength (specify all strengths to be used):	
D.3.10.1	Concentration unit:	

D.3.10.1 D.3.10.2 Concentration unit:

Concentration type ("exact number", "range", "more than" or "up to"):

D.3.11	Type of IMP	
Does the IMP	contain an active substance:	
D.3.11.1	Of chemical origin?	Yes •
D.3.11.2	Of biological / biotechnological origin (other than	No •
	Advanced Therapy IMP (ATIMP)?	
Is this a:		
D 2 11 2	Adversed Thereeve IMD (ATIMD)2	Na
D.3.11.3	Advanced Therapy IMP (ATIMP)?	No ● No ●
D.3.11.3.1 D.3.11.3.2	Somatic cell therapy medicinal product ¹⁶ ? Gene therapy medicinal product ¹⁷ ?	
D.3.11.3.2 D.3.11.3.3	Tissue Engineered Product ¹⁸ ?	
D.3.11.3.3	Combination ATIMP (i.e. one involving a medical	
D.3.11.3.4	device ¹⁹)?	
D.3.11.3.5	Has the Committee on Advanced Therapies issued a	No •
2.0.22.010	classification for this product?	
D.3.11.3.5.1	If 'Yes' please provide that classification and its reference	ce number:
D.3.11.4	Combination product that includes a device, but does	No •
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy?	NO •
D.3.11.5	Radiopharmaceutical medicinal product?	No •
D.3.11.6	Immunological medicinal product (such as vaccine,	No •
0.5.11.0	allergen, immune serum)?	
D.3.11.7	Plasma derived medicinal product?	No •
D.3.11.8	Extractive medicinal product?	No •
D.3.11.9	Recombinant medicinal product?	No •
D.3.11.10	Medicinal product containing genetically modified	No •
	organisms?	
D.3.11.10.1	Has the authorisation for contained use or release	No •
	been granted?	
D.3.11.10.2	Is it pending?	No •
D.3.11.11	Herbal medicinal product?	No •
D.3.11.12	Homeopathic medicinal product?	No •
D.3.11.13	Another type of medicinal product?	No •
D.3.11.13.1	If 'another type of medicinal product' specify the type of	of medicinal product:
D.3.12	Mode of action (<i>free text</i> ²⁰)	
D.3.13	Is it an IMP to be used in a first-in-human clinical trial?	No •
D.3.13.1	If 'Yes', are there risk factors identified, according to the	
D.4	SOMATIC CELL THERAPY INVESTIGATIONAL MEDIO	CINAL PRODUCT (NO GENETIC
	MODIFICATION)	
D.4.1	Origin of cells	
D.4.1.1	Autologous	No •

D.4.1.1	Autologous	NO •	
D.4.1.2	Allogeneic	No •	
D.4.1.3	Xenogeneic	No •	
D.4.1.3.1	If 'Yes', specify the species of origin:		
D.4.2	Type of cells		
D.4.2.1	Stem cells	No •	
D.4.2.2	Differentiated cells	No •	
D.4.2.2.1	If 'Yes', specify the type (e.g. keratinoc	ytes, fibroblasts, chondrocytes):	
D.4.2.3	Others:	No •	
D.4.2.3.1	If others, specify:		
1			

D.5	GENE THERAPY INVESTIGATIONAL MED	ICINAL PRODUCTS
D.5.1	Gene(s) of interest:	
D.5.2	In vivo gene therapy:	No •
D.5.3	Ex vivo gene therapy:	No •
D.5.4		
	Type of gene transfer product	
D.5.4.1	Nucleic acid (e.g. plasmid):	No •
	If 'Yes', specify if:	
D.5.4.1.1	Naked:	No •
D.5.4.1.2	Complexed	No •
		-
D.5.4.2	Viral vector:	No •
D.5.4.2.1	If 'Yes', specify the type: adenovirus, retrovin	rus, AAV,:
D.5.4.3	Others	No ●
D.5.4.3.1	If others, specify:	
D.5.5	Genetically modified somatic cells:	No •
	cify the origin of the cells:	
		No •
D.5.5.1	Autologous:	=
D.5.5.2	Allogeneic:	No •
D.5.5.3	Xenogeneic:	No •
D.5.5.3.1	If 'Yes', specify the species of origin:	
D.5.5.4	Specify type of cells (hematopoietic stem cell	s):
	TISSUE ENGINEERED PRODUCT on which determines that this is a Tissue Engine section E.1.1.	ered Product as opposed to a Cell Therapy product
D.6.1	Origin of cells	
D.6.1.1	Autologous	No •
D.6.1.2	Allogeneic	No •
D.6.1.3	Xenogeneic	No ●
D.6.1.3.1	If 'Yes', specify the species of origin:	
D.6.2	Type of cells	
D.6.2.1	Stem cells	No •
D.6.2.2	Differentiated cells	No •
D.6.2.2.1		
D.0.2.2.1	If 'Yes', specify the type of cells(e.g. kerating	cytes, indrodiasts, chondrocytes,).
D.6.2.3	Others:	No ●
D.6.2.3.1	If others, specify:	
D.7	PRODUCTS CONTAINING DEVICES (i.e. N	IEDICAL DEVICES, SCAFFULDS ETC.)
D.7.1	Give a brief description of the device:	
D.7.2	What is the name of the device?	

D.7.3 D.7.4 D.7.4.1 D.7.4.1.1 D.7.4.1.1	Is the device implantable? Does this product contain: A medical device? Does this medical device have a CE mark? The notified body is:	No ● No ● No ●
D.7.4.2 D.7.4.3 D.7.4.4 D.7.4.5 D.7.4.5.1	Bio-materials? Scaffolds? Matrices? Other? If other, specify:	No • No • No • No •

D.8 INFORMATION ON PLACEBO (if relevant; repeat as necessary)

D.8.1	Is there a placebo:	No •
	This we found have been also as the second have	
D.8.2	This refers to placebo number:	
D.8.3	Pharmaceutical form:	
D.8.4	Route of administration:	
D.8.5	Which IMP is it a placebo for? Specify IMP Number(s) from D.1.1	
D.8.5.1	Composition, apart from the active substance	e(s):
D.8.5.2	Is it otherwise identical to the IMP?	Yes ? No ? Not Answered ?
D.8.5.2.1	If not, specify major ingredients:	

D.9 SITE(S) WHERE THE QUALIFIED PERSON CERTIFIES BATCH RELEASE²²

This section is dedicated to **finished** IMPs, i.e. medicinal products randomised, packaged, labelled and certified for use in the clinical trial. If there is more than one site or more than one IMP is certified, use extra pages and give each IMP its number from section D.1.1 or D.8.2 In the case of multiple sites indicate the product certified by each site

The packaging and labelling is carried o 2005/28/EC (GCP Directive) If all these conditions are met tick ?and	(e.g. not overencapsulated) and ut for local use only as per article 9.2. of the Directive list the number(s) of each IMP including placebo from
PR1 PR2 PR3	ippiics
This site is responsible for certification of each IMP including placebo from section	
Manufacturer	?
Importer	?
Name of the organisation:	
Address:	
Street Address	
Country Give the manufacturing authorisation n	Imbori
	Is sourced from the EU market and Is used in the trial without modification(The packaging and labelling is carried of 2005/28/EC (GCP Directive) If all these conditions are met tick ?and sections D.1.1 and D.8.2 to which this a PR1 PR2 PR3 Who is responsible in the Communit This site is responsible for certification of each IMP including placebo from section please tick the appropriate box: Manufacturer Importer Name of the organisation: Address:

E. GENERAL INFORMATION ON THE TRIAL

This section should be used to provide information about the aims, scope and design of the trial. When the protocol includes a sub-study in the MS concerned section E.2.3 should be completed providing information about the sub-study. To identify it check the sub-study box in the 'Objective of the trial' question below.

E.1	MEDICAL CONDITION OR DISEASE UNDER INVESTIGATION		
E.1.1	Specify the medica English	al condition(s) to be investigated ²³ (free text): Subtype of Heart Failure with Preserved Ejection Fraction	
	Spanish	Subtipo de insuficiencia cardíaca con fracción de eyección preservada	
E.1.1.1	Medical condition i English	n easily understood language Subtype of Heart Failure	
	Spanish	Subtipo de insuficiencia cardíaca	
E.1.1.2 E.1.2	Therapeutic area Diseases [C] - Cardiovascular Diseases [C14] MedDRA version, system organ class, level, term and classification code ²⁴ : Version System Organ Class Classification Code Term Level 10007541 - Cardiac 10019280 Heart failures HLGT		
E.1.3	Is any of the condi	itions being studied a rare disease ²⁵ ? No •	
E.2	OBJECTIVE OF T	HE TRIAL	
E.2.1	Main objective: English	The primary objective of this study is to assess the safety profile of a triple therapy containing Vericiguat, L-Citrulline and Folate in HFpEF patients with optimal medical comorbidity treatment to standard of care	
	Spanish	El objetivo principal de este estudio es evaluar el perfil de seguridad de una terapia triple que contiene Vericiguat, L-Citrulina y folato en pacientes con HFpEF con tratamiento de comorbilidad médica óptimo según la práctica clínica habitual	
E.2.2	Secondary objectiv	/es:	
		Secondary objectives are to investigate possible benefits of treatment on patient reported outcomes and echocardiographic and laboratory findings.	
	Spanish	Los objetivos secundarios son investigar los posibles beneficios del tratamiento sobre los resultados informados por los pacientes y los hallazgos ecocardiográficos y de laboratorio.	
E.2.3 E.2.3.1	Is there a sub-study? No • If 'Yes', give the full title, date and version of each sub-study and their related objectives:		
E.3	PRINCIPAL INCLUSION CRITERIA (list the most important)		
	 English 1. Informed consent obtained before any trial-related activities. 2. Male or female, age above or equal to 18 years at the time of signing informed consent. 3. Stable NYHA Class II-III in the last 4-weeks. 4. LVEF ≥50% by echocardiography during screening. 5. No hospitalisations due to heart failure between screening and 		

- randomisation.
- 6. Able to perform the CPET at screening

7. KCCQ clinical summary score < 90 at screening.

8. At least one of the following:

a. Mean pulmonary wedge pressure \geq 15 mmHg or left ventricular end diastolic pressure (LVEDP) \geq 15 mmHg documented during catheterisation at rest or pulmonary artery (PA) diastolic pressure measured by implantable monitor \geq 15 mmHg or pulmonary wedge pressure or LVEDP \geq 25 mmHg documented during catheterisation at exercise.

b. NT-proBNP \geq 220 pg/mL (for patients with sinus rhythm) or NTproBNP \geq 660 pg/mL (for patients with persistent/permanent atrial fibrillation); in combination with at least one of the following (documented by echocardiography within 12 months prior to or at screening):

i. Septal \acute{e} < 7 cm/sec or lateral \acute{e} < 10 cm/sec or average E/ \acute{e} ≥ 15 ii. PA systolic pressure > 35 mmHg

iii. Left atrial (LA) enlargement (LA width \geq 3.8 cm or LA length \geq 5.0 cm or LA area \geq 20.0 cm2 or LA volume \geq 55 mL or LA volume index \geq 29 mL/m2)

iv. LV hypertrophy with septal thickness or posterior wall thickness \geq 1.2 cm

c. Hospitalisation with a primary diagnosis of decompensated heart failure which required intravenous (IV) loop diuretic treatment, within the previous 12 months in combination with at least two of the following (documented by echocardiography within 12 months prior to or at screening):

i. Septal é < 7 cm/sec or lateral é < 10 cm/sec or average E/é \geq 15 ii. PA systolic pressure > 35 mmHg

iii. LA enlargement (LA width \geq 3.8 cm or LA length \geq 5.0 cm or LA area \geq 20.0 cm2 or LA volume \geq 55 mL or LA volume index \geq 29 mL/m2) iv. LV hypertrophy with septal thickness or posterior wall thickness \geq 1.2 cm

v. Ongoing use of diuretic therapy for at least 30 days prior to screening 9. Mechanism-based diagnostics inclusion: In patients according to 1-8, plasma levels NOX5 \geq 105 ng/ml or upregulated apo-sGC levels indicated by an sGCa/sGCs ratio higher than 1.05 (a.u.). NOX5 protein levels are stable enough to be measured in plasma using a NOX5 ELISA for which plasma samples will be diluted 1:200 before measurements. Apo-sGC levels are measured in a blood cell-based assay in which aposGC/sGC ratio is demonstrated by the phospho- VASP response induced by an sGC activator and divided by the response induced by an sGC stimulator.

Spanish 1. Consentimiento informado obtenido antes de cualquier actividad relacionada con el ensayo.

2. Hombre o mujer, edad mayor o igual a 18 años al momento de firmar el consentimiento informado.

3. Clase NYHA II-III estable en las últimas 4 semanas.

4. FEVI ≥50% por ecocardiografía durante la selección.

5. Sin hospitalizaciones por insuficiencia cardíaca entre la selección y la aleatorización.

6. Capacidad para realizar el CPET en la selección

7. Puntuación del resumen clínico KCCQ < 90 en la selección.

8. Se cumplen al menos una de las siguientes:

a. Presión capilar pulmonar ≥ 15mmHg o presión diastólica final del ventrículo izquierdo (LVEDP) ≥ 15mmHg documentada durante el cateterismo en reposo o presión diastólica pulmonar arterial medida por un monitor implantable ≥ 15mmHg o presión capilar pulmonar o LVEPD ≥ 25mmHg documentada durante el cateterismo en el ejercicio. b.NT-proBNP ≥ 220 pg/mL (para pacientes con ritmo sinusal) o NTproBNP ≥ 660 pg/mL (para pacientes con fibrilación auricular persistente/permanente); en combinación con al menos una de las siguientes condiciones (documentado por ecocardiografía en los 12

meses previos a la selección: i. Septal é < 7 cm/sec o lateral é < 10 cm/sec o promedio E/é ≥ 15.
ii. Presión sistólica pulmonar arterial > 35 mmHg
iii. Dilatación aurícula izquierda (AI) (ancho AI ≥ 3.8 cm o largo AI ≥ 5.0 cm o área AI ≥ 20.0 cm2 o volumen AI ≥ 55 mL o índice de volumen de AI ≥ 29 mL/m2)
iv. Hipertrofia del ventrículo izquierdo con engrosamiento del septo o de la pared posterior ≥ 1.2 cm.
c. Hospitalización con un diagnóstico primario de descompensación de la
insuficiencia cardíaca con requerimientos de tratamiento intravenoso de diuréticos de asa en los 12 meses previos en combinación con al menos dos de las siguientes condiciones (documentado por ecocardiografía en los 12 meses previos a la selección):
i. Septal é < 7 cm/sec o lateral é < 10 cm/sec o promedio E/é ≥ 15. ii. Presión sistólica pulmonar arterial > 35 mmHg
iii. Dilatación aurícula izquierda (AI) (ancho AI \ge 3.8 cm o largo AI \ge 5.0 cm o área AI \ge 20.0 cm2 o volumen AI \ge 55 mL o índice de volumen de AI \ge 29 mL/m2)
iv. Hipertrofia del ventrículo izquierdo con engrosamiento del septo o de la pared posterior ≥ 1.2 cm
v. Uso de terapia diurética en los 30 días previos a la visita de selección. 9. Inclusión de diagnósticos basados en mecanismos: En pacientes
según 1-8, niveles plasmáticos de NOX5 \ge 105 ng/ml o niveles de apo- sGC regulados al alza indicados por una relación sGCa/sGCs superior a
1,05 (a.u.). proteína NOX5 los niveles son lo suficientemente estables para ser medidos en plasma utilizando un ELISA NOX5 para el cual las muestras de plasma se diluirán 1:200 antes de las mediciones. Niveles de Apo-sGC
se miden en un ensayo basado en células sanguíneas en el que la
relación apo-sGC/sGC se demuestra mediante el fosfo-Respuesta VASP
inducida por un activador de sGC y dividida por la respuesta inducida po un estimulador de sGC.

E.4	PRINCIPAL EXCLUSION CRITERIA (list the most important)		
E.4	PRINCIPAL E English	 EXCLUSION CRITERIA (list the most important) 1. Has SBP <110 mm Hg or symptomatic hypotension. 2. Prior history of LVEF<50% 3. Heart failure decompensation in the last 4 weeks. 4. Has a known allergy or sensitivity to vericiguat, any of its constituents, or any other sGC stimulator. 5. Has amyloidosis or sarcoidosis. 6. Has primary valvular heart disease requiring surgical procedure or intervention or has undergone a vascular surgical procedure or intervention within 3 months before randomization. 7. Has hypertrophic cardiomyopathy. 8. Has acute myocarditis or Takotsubo cardiomyopathy. 9. Has received a heart transplant. 10. Has tachycardia-induced cardiomyopathy and/or uncontrolled tachyarrhythmia. 11. Has acute coronary syndrome (unstable angina, NSTEMI, or STEMI), undergone CABG or PCI within 3 months before randomization. 12. Has symptomatic carotid stenosis, TIA, or stroke within 3 months before randomization. 13. Has a history of repaired or unrepaired simple congenital heart disease (eg, atrial or ventricular septal defects, or patent ductus arteriosus) with ongoing hemodynamically significant residual lesions, or any history of complex congenital heart disease (eg, tetralogy of Fallot, transposition of the great arteries, single ventricle disease) regardless of repair status. 	

	 14. Has active endocarditis or constrictive pericarditis. 15. Has an eGFR based on the CKD-EPI Creatinine Equation of <15 mL/min/1.73 m2 within 30 days before randomization or is on chronic dialysis. For participants with multiple eGFR results during screening, the most recent value will be used to determine eligibility at the Randomization Visit. 16. Has severe hepatic insufficiency such as with hepatic encephalopathy, hepatic laboratory abnormalities (ALT or AST ≥3 × ULN or total bilirubin ≥2 × ULN) or ALBI Grade 3 as defined in Appendix 8 [Fragaki, M., et al 2019]. Screening albumin, ALT, AST, and total bilirubin results within 30 days before randomization may be used for assessment of laboratory abnormalities or the calculation of the ALBI score. For participants with multiple albumin and/or total bilirubin results during screening, the most recent value for each test will be used to calculate ALBI score. 17. Has malignancy or other noncardiac condition limiting life expectancy to <3 years. 18. Requires continuous home oxygen for severe pulmonary disease. 19. Has interstitial lung disease. 20. Has concurrent or anticipated concomitant use of PDE5 inhibitors such as vardenafil, tadalafil, and sildenafil during the study. 21. Has participated in another interventional clinical study or has been treated with another investigational product ≤30 days before randomization or plans to participate in any other study or study intervention during this study. 23. Has a recent history (within the last year) of drug or alcohol abuse or dependence. 24. Is pregnant or breastfeeding or plans to become pregnant or to breastfeed during the study. 25. Has a medical disorder, condition, or history thereof that in the opinion of the investigator would impair the participant's ability to participate in or complete the study. 26. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or child) wh
Spanish	 Hipotensión arterial sintomática o TAS < 110 mmHg. Historial previo de FEVI < 50% Alergia o sensibilidad conocida al vericiguat o alguno de sus constituyentes o a cualquier otro estimulador de GCs Amiloidosis o Sarcoidosis Enfermedad cardiaca valvular primaria que requiera procedimiento quirúrgico o intervención o que haya requerido una intervención quirúrgica vascular o intervención en los 3 meses previos a la aleatorización Cardiomiopatía hipertrófica Miocarditis aguda o miocardiopatía de Takotsubo Trasplante cardiaco previo Miocardiopatía inducida por taquicardia y/o taquiarritmia no controlada Síndrome coronario agudo (angina inestable, IMSEST, IAMCEST) que requieran CABG o PCI en los 3 meses previos a la aleatorización Estenosis carotídea sintomática, AIT o accidente cerebrovascular en los 3 meses previos a la aleatorización Historial de cardiopatía congénita reparada o no reparada (ej, defecto septal auricular o ventricular o patent ductus arteriosus) con lesiones residuales hemodinámicamente significativas en curso o historial de cardiopatías complejas (ej, tetralogía de Fallot, transposición de grandes arterias, enfermedad ventrículo único) con independencia del

E.5	END POINT(S):		
E.5.1	Primary End Point (repeat as necessary) ²⁶		
	English	To evaluate safety profile: All adverse drug reactions (ADR)	
	Spanish	Evaluar el perfil de seguridad: Todas las reacciones adversas a los medicamentos (RAM)	
E.5.1.1	Timepoint(s) of eva	aluation of this end point	
English From Baseline (Visit 2) to end of study (Visit 4)		From Baseline (Visit 2) to end of study (Visit 4)	
	Spanish	Desde la visita basal (visita 2) hasta el final del estudio (Visita 4)	
E.5.2	Secondary End Poir	nt (repeat as necessary)	
trial period compared to screening; change in laboratory asse		All cause mortality over the trial period; change in vital signs over the trial period compared to screening; change in laboratory assessments over the trial course compared to screening; number of heart failure related hospital admission over the trial period	
	Spanish	Todas las causas de muerte durante el período del estudio; cambios en los signos vitales durante el período del estudio comparado con la	

selección; cambios en las pruebas de laboratorio durante el estudio comparadas con las selección; número de hospitalizaciones relacionadas con la insuficiencia cardíaca durante el período del estudio

E.5.2.1 Timepoint(s) of evaluation of this end point English All visits

Spanish

Тос	las	las	visitas	
100	ias	ias	visitas	

E.6	5.6 SCOPE OF THE TRIAL – Tick all boxes where applicable	
E.6.1	Diagnosis	No •
E.6.2	Prophylaxis	No •
E.6.3	Therapy	Yes •
E.6.4	Safety	Yes ●
E.6.5	Efficacy	No •
E.6.6	Pharmacokinetic	No •
E.6.7	Pharmacodynamic	No •
E.6.8	Bioequivalence	No •
E.6.9	Dose Response	No •
E.6.10	Pharmacogenetic	No •
E.6.11	Pharmacogenomic	No •
E.6.12	Pharmacoeconomic	No •
E.6.13	Others	No •
E.6.13.1	If others, specify:	

E.7	TRIAL TYPE AND PHASE ²⁷		
E.7.1	Human pharmacology (Phase I)	No •	
Is it:			
E.7.1.1	First administration to humans	No •	
E.7.1.2	Bioequivalence study	No •	
E.7.1.3	Other:	No •	
E.7.1.3.1	If other, please specify:		
E.7.2	Therapeutic exploratory (Phase II)	Yes •	
E.7.3	Therapeutic confirmatory (Phase III)	No •	
E.7.4	Therapeutic use(Phase IV)	No •	

E.8	DESIGN OF THE TRIAL	
E.8.1	Controlled	Yes ∙
	If 'Yes', specify:	
E.8.1.1	Randomised:	Yes •
E.8.1.2	Open:	Yes •
E.8.1.3	Single blind:	No •
E.8.1.4	Double blind:	No •
E.8.1.5	Parallel group:	Yes •
E.8.1.6	Cross over:	No •
E.8.1.7	Other:	No •
E.8.1.7.1	If other specify:	
E.8.2	If controlled, specify the comparator:	
E.8.2.1	Other medicinal product(s)	Yes •
E.8.2.2	Placebo	No •
E.8.2.3	Other	No •
E.8.2.3.1	If 'Yes' to other, specify :	
E.8.2.4	Number of treatment arms in the trial	2
E.8.3	Single site in the Member State concerned (see als	
E.8.4	Multiple sites in the Member State concerned(see also section G): No •	
E.8.4.1	Number of sites anticipated in Member State concerned	
E.8.5	Multiple Member States:	No •
E.8.5.1	Number of sites anticipated in the EEA:	

E.8.6 Trial involving sites outside the EEA: E.8.6.1 Trial being conducted both within and outside the EEA: No • E.8.6.2 Trial being conducted completely outside of the EEA: No • E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned: E.8.6.4 If E.8.6.1 or E.8.6.2 are Yes, specify the number of sites anticipated outside of the EEA: E.8.7 Yes • Trial having an independent data monitoring committee: Definition of the end of trial: If it is the last visit of the last subject, please enter "LVLS". If it is not E.8.8 LVLS provide the definition: English Last visit last subject (LVLS) Spanish Última visita del último sujeto E.8.9 Initial estimate of the duration of the trial²⁸ (years, months and days) years months days E.8.9.1 In the Member State concerned E.8.9.2 In all countries concerned by the trial years months days Proposed date of start of recruitment E.8.10 In the Member State concerned E.8.10.1 E.8.10.2 In any country

F. POPULATION OF TRIAL SUBJECTS

F.1.1 Are the trial subjects under 18? No • If Yes', specify the estimated number of subjects planned in each age range for the whole trial: Approx. No. of patients ²⁹ F.1.1.1 In utero () No • F.1.1.2 Preterm newborn infants (up to () No • F.1.1.3 Newborns (0-27 days) () No • F.1.1.4 Infants and toddlers (28 days - () No • F.1.1.5 Children (2-11 years) () No • F.1.1.6 Adolts (18-64 years) (21) Yes • F.1.3 Elderly (>= 65 years) (16) Yes • F.2.1 Female Yes • • F.3.2 Patients' Yes • • F.3.3 Specific vulnerable populations No • • F.3.3 Specific vulnerable populations No • • F.3.3.4 Healthy volunteers No • • F.3.3.2 Women of child bearing potential not using No • • F.3.3.4 Hoalthy women No • • F.3.3.4 Wormen of child bearing potential using contraception No •<	F.1	AGE RANGE	
planned in each age range for the whole trial: Approx. No. of patients ²⁹ F.1.1.1 In utero () No • F.1.1.2 Preterm newborn infants (up to () No • gestational age < 37 weeks)	F.1.1		No •
Approx. No. of patients ²⁹ F.1.1.1 In utero F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks)			
F.1.1.1 In utero () No • F.1.1.2 Preterm newborn infants (up to () No • gestational age < 37 weeks)		planned in each age range for the whole trial:	
F.1.1.1 In utero () No • F.1.1.2 Preterm newborn infants (up to () No • gestational age < 37 weeks)			
F.1.1.2 Preterm newborn infants (up to () No • gestational age < 37 weeks)		•	
gestational age < 37 weeks)F.1.1.3Newborns (0-27 days)()No •F.1.1.4Infants and toddlers (28 days -()No •23 months)F.1.1.5Children (2-11 years)()No •F.1.1.5Children (2-11 years)()No •F.1.1.6Adolescents (12-17 years)()No •F.1.2Adults (18-64 years)(21)Yes •F.1.3Elderly (>= 65 years)(16)Yes •F.2GENDERF.2.1FemaleYes •F.2.2MaleYes •F.3.1Healthy volunteersNo •F.3.2PatientsYes •F.3.3Specific vulnerable populationsNo •F.3.3.1Women of child bearing potential not using contraceptionNo •F.3.3.2Women of child bearing potential using contraceptionNo •F.3.3.3Pregnant womenNo •F.3.3.4Nursing womenNo •F.3.3.5Emergency situationNo •F.3.3.6Subjects incapable of giving consent personallyNo •F.3.3.7Others:No •F.3.3.7.1If 'Yes', specify:No •			No •
F.1.1.4Infants and toddlers (28 days - 23 months)No •F.1.1.5Children (2-11 years)()No •F.1.1.6Adolescents (12-17 years)()No •F.1.1.7Children (2-11 years)()No •F.1.2Adults (18-64 years)(21)Yes •F.1.3Elderly (>= 65 years)(16)Yes •F.2GENDERYes •F.2.1FemaleYes •F.2.2MaleYes •F.3.3GROUP OF TRIAL SUBJECTSF.3.4Healthy volunteersNo •F.3.3Specific vulnerable populationsNo •F.3.3.1Women of child bearing potential not using contraceptionNo •F.3.3.2Women of child bearing potential using contraceptionNo •F.3.3.3Pregnant womenNo •F.3.3.4Nursing womenNo •F.3.3.5Emergency situationNo •F.3.3.6Subjects incapable of giving consent personallyNo •F.3.3.7Others:No •F.3.3.7.1If 'Yes', specify:No •	F.1.1.2		No •
23 months)F.1.1.5Children (2-11 years)()No •F.1.1.6Adolescents (12-17 years)()No •F.1.2Adults (18-64 years)(21)Yes •F.1.3Elderly (>= 65 years)(16)Yes •F.2GENDERYes •F.2.1FemaleYes •F.2.2MaleYes •F.3GROUP OF TRIAL SUBJECTSF.3.1Healthy volunteersNo •F.3.2PatientsYes •F.3.3Specific vulnerable populationsNo •F.3.3.4Women of child bearing potential not using contraceptionNo •F.3.3.5Emergency situationNo •F.3.3.6.1If Yes', specify:No •F.3.3.7Others:No •F.3.3.7.1If Yes', specify:No •	F.1.1.3	Newborns (0-27 days) ()	No •
F.1.1.6 Adolescents (12-17 years) () No • F.1.2 Adults (18-64 years) (21) Yes • F.1.3 Elderly (>= 65 years) (16) Yes • F.2 GENDER	F.1.1.4		No •
F.1.2 Adults (18-64 years) (21) Yes • F.1.3 Elderly (>= 65 years) (16) Yes • F.2 GENDER Yes • F.2.1 Female Yes • F.2.2 Male Yes • F.3 GROUP OF TRIAL SUBJECTS Yes • F.3.1 Healthy volunteers No • F.3.2 Patients Yes • F.3.3 Specific vulnerable populations No • F.3.3 Specific vulnerable populations No • F.3.3.1 Women of child bearing potential not using contraception No • F.3.3.2 Women of child bearing potential using contraception No • F.3.3.3 Pregnant women No • F.3.3.4 Nursing women No • F.3.3.5 Emergency situation No • F.3.3.6.1 If 'Yes', specify: No • F.3.3.7 Others: No • F.3.3.7.1 If 'Yes', specify: No •	F.1.1.5	Children (2-11 years) ()	No •
F.1.3 Elderly (>= 65 years) (16) Yes • F.2 GENDER F.2.1 Female Yes • F.2.2 Male Yes • F.3.1 Fealthy volunteers No • F.3.2 Patients Yes • F.3.3 Specific vulnerable populations No • F.3.3.1 Women of child bearing potential not using contraception No • F.3.3.2 Women of child bearing potential using contraception No • F.3.3.3 Pregnant women No • F.3.3.4 Nursing women No • F.3.3.5 Emergency situation No • F.3.3.6 Subjects incapable of giving consent personally No • F.3.3.7 Others: No • F.3.3.7.1 If 'Yes', specify: No •	F.1.1.6	Adolescents (12-17 years) ()	No •
F.2 GENDER F.2.1 Female Yes • F.2.2 Male Yes • F.3 GROUP OF TRIAL SUBJECTS No • F.3.1 Healthy volunteers No • F.3.2 Patients Yes • F.3.3 Specific vulnerable populations No • F.3.3 Specific vulnerable populations No • F.3.3.1 Women of child bearing potential not using contraception No • F.3.3.2 Women of child bearing potential using contraception No • F.3.3.3 Pregnant women No • F.3.3.4 Nursing women No • F.3.3.5 Emergency situation No • F.3.3.6 Subjects incapable of giving consent personally No • F.3.3.7 Others: No • F.3.3.7.1 If 'Yes', specify: No •			Yes •
F.2.1Female F.2.2Yes • Yes •F.2.2MaleYes •F.3.1Healthy volunteers F.3.2No • Yes •F.3.2PatientsYes •F.3.3Specific vulnerable populations contraceptionNo •F.3.3.1Women of child bearing potential not using contraceptionNo •F.3.3.2Women of child bearing potential using contraceptionNo •F.3.3.3Pregnant women F.3.3.4No •F.3.3.5Emergency situation F.3.3.6No •F.3.3.6Subjects incapable of giving consent personally F.3.3.7No •F.3.3.7Others: F.3.3.7.1If 'Yes', specify:	F.1.3	Elderly (>= 65 years) (16)	Yes •
F.2.1Female F.2.2Yes • Yes •F.2.2MaleYes •F.3.1Healthy volunteers F.3.2No • Yes •F.3.2Patients PatientsYes • Yes •F.3.3Specific vulnerable populations contraceptionNo • Yes •F.3.3.1Women of child bearing potential not using contraceptionNo • No •F.3.3.2Women of child bearing potential using contraception F.3.3.3No • No •F.3.3.4Nursing women F.3.3.5No • Emergency situation F.3.3.6No • Subjects incapable of giving consent personally F.3.3.7No • No •F.3.3.7Others: F.3.3.7.1No •No •			
F.2.2MaleYes •F.3.GROUP OF TRIAL SUBJECTSF.3.1Healthy volunteersF.3.2PatientsF.3.3Specific vulnerable populationsF.3.3.1Women of child bearing potential not using contraceptionF.3.3.2Women of child bearing potential using contraceptionF.3.3.3Pregnant womenF.3.3.4Nursing womenF.3.3.5Emergency situationF.3.3.6Subjects incapable of giving consent personallyF.3.3.7Others:F.3.3.7If 'Yes', specify:			
F.3GROUP OF TRIAL SUBJECTSF.3.1Healthy volunteersNo •F.3.2PatientsYes •F.3.3Specific vulnerable populationsNo •F.3.3.1Women of child bearing potential not using contraceptionNo •F.3.3.2Women of child bearing potential using contraceptionNo •F.3.3.3Pregnant womenNo •F.3.3.4Nursing womenNo •F.3.3.5Emergency situationNo •F.3.3.6Subjects incapable of giving consent personallyNo •F.3.3.7Others:No •F.3.3.7.1If 'Yes', specify:No •			
F.3.1Healthy volunteersNo •F.3.2PatientsYes •F.3.3Specific vulnerable populationsNo •F.3.3.1Women of child bearing potential not using contraceptionNo •F.3.3.2Women of child bearing potential using contraceptionNo •F.3.3.3Pregnant womenNo •F.3.3.4Nursing womenNo •F.3.3.5Emergency situationNo •F.3.3.6Subjects incapable of giving consent personallyNo •F.3.3.7Others:No •F.3.3.7.1If 'Yes', specify:No •	F.2.2	Male	Yes •
F.3.2PatientsYesF.3.3Specific vulnerable populationsNoF.3.3.1Women of child bearing potential not using contraceptionNoF.3.3.2Women of child bearing potential using contraceptionNoF.3.3.3Pregnant womenNoF.3.3.4Nursing womenNoF.3.3.5Emergency situationNoF.3.3.6Subjects incapable of giving consent personallyNoF.3.3.7Others:NoF.3.3.7.1If 'Yes', specify:No	F.3	GROUP OF TRIAL SUBJECTS	
F.3.3Specific vulnerable populationsNoF.3.3.1Women of child bearing potential not using contraceptionNoF.3.3.2Women of child bearing potential using contraceptionNoF.3.3.3Pregnant womenNoF.3.3.4Nursing womenNoF.3.3.5Emergency situationNoF.3.3.6Subjects incapable of giving consent personallyNoF.3.3.7Others:NoF.3.3.7If 'Yes', specify:No	F.3.1	Healthy volunteers	No •
F.3.3.1Women of child bearing potential not using contraceptionNo •F.3.3.2Women of child bearing potential using contraceptionNo •F.3.3.3Pregnant womenNo •F.3.3.4Nursing womenNo •F.3.3.5Emergency situationNo •F.3.3.6Subjects incapable of giving consent personallyNo •F.3.3.7Others:No •F.3.3.7If 'Yes', specify:No •	F.3.2	Patients	Yes •
contraceptionNo •F.3.3.2Women of child bearing potential using contraceptionNo •F.3.3.3Pregnant womenNo •F.3.3.4Nursing womenNo •F.3.3.5Emergency situationNo •F.3.3.6Subjects incapable of giving consent personallyNo •F.3.3.7Others:No •F.3.3.7.1If 'Yes', specify:No •	F.3.3		No •
F.3.3.3Pregnant womenNo •F.3.3.4Nursing womenNo •F.3.3.5Emergency situationNo •F.3.3.6Subjects incapable of giving consent personallyNo •F.3.3.6.1If 'Yes', specify:No •F.3.3.7Others:No •F.3.3.7.1If 'Yes', specify:	F.3.3.1		No •
F.3.3.4Nursing womenNo •F.3.3.5Emergency situationNo •F.3.3.6Subjects incapable of giving consent personallyNo •F.3.3.6.1If 'Yes', specify:No •F.3.3.7Others:No •F.3.3.7.1If 'Yes', specify:	F.3.3.2	Women of child bearing potential using contraceptio	n No •
F.3.3.5Emergency situationNo •F.3.3.6Subjects incapable of giving consent personallyNo •F.3.3.6.1If 'Yes', specify:No •F.3.3.7Others:No •F.3.3.7.1If 'Yes', specify:	F.3.3.3	Pregnant women	No •
F.3.3.6Subjects incapable of giving consent personallyNo •F.3.3.6.1If 'Yes', specify:No •F.3.3.7Others:No •F.3.3.7.1If 'Yes', specify:			No •
F.3.3.6.1 If 'Yes', specify: F.3.3.7 Others: F.3.3.7.1 If 'Yes', specify:			No •
F.3.3.7 Others: No • F.3.3.7.1 If 'Yes', specify:			No •
F.3.3.7.1 If 'Yes', specify:			
			No •
F.4 PLANNED NUMBER OF SUBJECTS TO BE INCLUDED:	F.3.3.7.1	If 'Yes', specify:	
F.4 PLANNED NUMBER OF SUBJECTS TO BE INCLUDED:			
	F.4	PLANNED NUMBER OF SUBJECTS TO BE INCLU	DED:

F.4.1 In the member state F.4.2 For a multinational trial:

F.4.2.1 In the EEA

F.4.2.2 In the whole clinical trial

F.5 PLANS FOR TREATMENT OR CARE AFTER THE SUBJECT HAS ENDED HIS/HER **PARTICIPATION IN THE TRIAL. please specify** (free text): English At the final visit of the study [Visit 4 (84 ± 10 days)], patients will be asked to return the medication left over from the study, the results of the study will be carefully explained and the doctor will continue with the treatment of the patients following the practice usual clinic of the center. A telephone contact will be made 30 days after the end of the treatment. This call will be made to exclude the possibility of adverse effects after the completion of the study. Spanish En la visita final del estudio [Visita 4 ($84 \pm 10 dias$)], se solicitara a los pacientes que devuelvan la medicación sobrante del estudio, se explicaran detenidamente los resultados del estudio y el medico continuará con el tratamiento de los pacientes siguiendo la práctica

21

clínica habitual del centro. Se realizará un contacto telefónico 30 días después del final del tratamiento. Esta llamada se realizará para excluir la posibilidad de efectos adversos después de la finalización del estudio.

G. CLINICAL TRIAL SITES/INVESTIGATORS IN THE MEMBER STATE CONCERNED BY THIS REQUEST

G.1	CO-ORDINATING INVESTIGATOR (for multicentre trial) and principal investigator (for single centre trial)		
G.1.1	Given name:	Julio	
G.1.2	Middle name, if applicable:		
G.1.3	Family name:	Núñez Villota	
G.1.4	Qualification (MD)		
G.1.5	Professional address:		
G.1.5	Institution name	HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA#Cod.	
		CNH: 460044#	
G.1.5	Institution department	Servicio de Cardiología	
G.1.5.1	Street address	AVENIDA BLASCO IBAÑEZ 17	
G.1.5.2	Town/city	València	
G.1.5.3	Post code	46010	
G.1.5.4	Country	Spain	
G.1.6	Telephone number:	-	
G.1.7	Fax number:		
G.1.8	E-mail:		

G.2	PRINCIPAL INVESTIGATORS (for multicentre trial ; where necessary, use additional forms)
G.2.1	Given name:
G.2.2	Middle name, if applicable:
G.2.3	Family name:
G.2.4	Qualification (MD)
G.2.5	Professional address:
G.2.5	Institution name
G.2.5	Institution department
G.2.5.1	Street address
G.2.5.2	Town/city
G.2.5.3	Post code
G.2.5.4	Country
G.2.6	Telephone number:
G.2.7	Fax number:
G.2.8	E-mail:

G.3 CENTRAL TECHNICAL FACILITIES TO BE USED IN THE CONDUCT OF THE TRIAL

Laboratory or other technical facility, in which the measurement or assessment of the main evaluation criteria are centralised (repeat as needed for multiple organisations).

G.3.1	Name of organisation:
G.3.2	Department
G.3.3	Name of contact person:
G.3.3.1	Given name
G.3.3.2	Middle name
G.3.3.3	Family name
G.3.4	Address:
G.3.4.1	Street address
G.3.4.2	Town/city
G.3.4.3	Post code
G.3.4.4	Country
G.3.5	Telephone number:
G.3.6	Fax number:
G.3.7	E-mail:
G.3.8	Enter the details of any duties subcontracted to this central technical facility in this trial

G.3.8.1	Routine clinical pathology testing	Yes ? No ? Not Answered ?
G.3.8.2	Clinical chemistry	Yes ? No ? Not Answered ?
G.3.8.3	Clinical haematology	Yes ? No ? Not Answered ?
G.3.8.4	Clinical microbiology	Yes ? No ? Not Answered ?
G.3.8.5	Histopathology	Yes ? No ? Not Answered ?
G.3.8.6	Serology/ endocrinology	Yes ? No ? Not Answered ?
G.3.8.7	Analytical chemistry	Yes ? No ? Not Answered ?
G.3.8.8	ECG analysis/ review	Yes ? No ? Not Answered ?
G.3.8.9	Medical image analysis/ review - X-ray, MRI, ultrasound, etc.	Yes ? No ? Not Answered ?
G.3.8.10	Primary/ surrogate endpoint test	Yes ? No ? Not Answered ?
G.3.8.11	Other Duties subcontracted?	Yes ? No ? Not Answered ?
G.3.8.11.1	If 'Yes', specify the other duties	

G.4	NETWORKS TO BE INVOLVED IN THE TRIAL (e.g. Paediatric Networks involved in the trial)		
G.4.1	Name of organisation:		
G.4.2	Name of contact person:		
G.4.2.1	Given name		
G.4.2.2	Middle name		
G.4.2.3	Family name		
G.4.3	Address:		
G.4.3.1	Street address		
G.4.3.2	Town/city		
G.4.3.3	Post code		
G.4.3.4	Country		
G.4.4	Telephone number:		
G.4.5	Fax number:		
G.4.6	E-mail:		
G.4.7	Activities carried out by the network:		
5.1.7	Activities carried out by the network.		
G.5	ORGANISATIONS TO WHOM THE SPONSOR HAS TRA	ANSFERRED TRIAL RELATED	
	DUTIES AND FUNCTIONS		
G.5.1	Has the sponsor transferred any major or all the sp		
	related duties and functions to another organisation		
	related duties and functions to another organisation necessary for multiple organisations:		
	related duties and functions to another organisation necessary for multiple organisations: Organisation name:		
Repeat as G.5.1.1 G.5.1.2	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department		
Repeat as G.5.1.1	related duties and functions to another organisation necessary for multiple organisations: Organisation name:		
Repeat as G.5.1.1 G.5.1.2	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person :		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address:		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4 G.5.1.5	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country Telephone number:		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4 G.5.1.5 G.5.1.6	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country Telephone number: Fax number:		
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4 G.5.1.5 G.5.1.6 G.5.1.7	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail:	n or third party?	
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4 G.5.1.5 G.5.1.6 G.5.1.7 G.5.1.8	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail: All tasks of the sponsor	n or third party? Yes ? No ? Not Answered ?	
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4 G.5.1.5 G.5.1.6 G.5.1.7 G.5.1.8 G.5.1.9	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail: All tasks of the sponsor Monitoring	n or third party? Yes ? No ? Not Answered ? Yes ? No ? Not Answered ?	
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4 G.5.1.5 G.5.1.6 G.5.1.7 G.5.1.8	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail: All tasks of the sponsor Monitoring Regulatory (e.g. preparation of applications to CA and ethics committee)	n or third party? Yes ? No ? Not Answered ?	
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4 G.5.1.5 G.5.1.6 G.5.1.7 G.5.1.8 G.5.1.9 G.5.1.10 G.5.1.11	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail: All tasks of the sponsor Monitoring Regulatory (e.g. preparation of applications to CA and ethics committee) Investigator recruitment	n or third party? Yes ? No ? Not Answered ? Yes ? No ? Not Answered ?	
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4 G.5.1.5 G.5.1.6 G.5.1.7 G.5.1.8 G.5.1.9 G.5.1.10	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail: All tasks of the sponsor Monitoring Regulatory (e.g. preparation of applications to CA and ethics committee)	n or third party? Yes ? No ? Not Answered ? Yes ? No ? Not Answered ? Yes ? No ? Not Answered ? Yes ? No ? Not Answered ?	
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4 G.5.1.5 G.5.1.6 G.5.1.7 G.5.1.8 G.5.1.9 G.5.1.10 G.5.1.11	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail: All tasks of the sponsor Monitoring Regulatory (e.g. preparation of applications to CA and ethics committee) Investigator recruitment	n or third party? Yes ? No ? Not Answered ? Yes ? No ? Not Answered ?	
Repeat as G.5.1.1 G.5.1.2 G.5.1.3 G.5.1.3.1 G.5.1.3.2 G.5.1.3.3 G.5.1.4 G.5.1.4.1 G.5.1.4.2 G.5.1.4.3 G.5.1.4.4 G.5.1.5 G.5.1.6 G.5.1.7 G.5.1.8 G.5.1.9 G.5.1.10 G.5.1.11 G.5.1.12	related duties and functions to another organisation necessary for multiple organisations: Organisation name: Organisation department Name of contact person : Given name Middle name Family name Address: Street address Town/city Post code Country Telephone number: Fax number: E-mail: All tasks of the sponsor Monitoring Regulatory (e.g. preparation of applications to CA and ethics committee) Investigator recruitment IVRS ³⁰ – treatment randomisation	n or third party? Yes ? No ? Not Answered ? Yes ? No ? Not Answered ?	

G.5.1.16Quality assurance auditingYes ? No ? Not Answered ?G.5.1.17Statistical analysisYes ? No ? Not Answered ?G.5.1.18Medical writingYes ? No ? Not Answered ?G.5.1.19Other duties subcontracted?Yes ? No ? Not Answered ?G.5.1.19.1If 'Yes' to other, please specify:Yes ? No ? Not Answered ?

H. COMPETENT AUTHORITY / ETHICS COMMITTEE IN THE MEMBER STATE CONCERNED BY THIS REQUEST

H.1 TYPE OF APPLICATION

If this application is addressed to the Competent Authority, please tick the Ethics Committee box and give information on the Ethics committee concerned. If this application is addressed to the Ethics Committee, please tick the Competent Authority box and give the information on the Competent Authority concerned.

H.1.1	Competent Authority	No •	
H.1.2	Ethics Committee	Yes ●	

H.2	INFORMATION ON ETHICS COMMITTEE	
H.2.1	Name:	CEIm del Hospital Clínico Universitario de Valencia
H.2.2	Address	
H.2.2.1	Street address	Avda. Vicente Blasco Ibáñez, 17
H.2.2.2	Town/city	VALENCIA
H.2.2.3	Post code	46010
H.2.2.4	Country	Spain
H.2.3	Date of submission:	
H.3	OPINION	
H.3.1	To be requested	No •
H.3.2	Pending	No •
H.3.3	Given	No •
	If 'Given', specify:	
H.3.3.1	Date of opinion:	
H.3.3.2	Opinion favourable	No •
H.3.3.3	Opinion not favourable	No ●
	If not favourable, give:	
H.3.3.3.1	· •	
H.3.3.3.2	The eventual anticipated date	e of resubmission:

I. SIGNATURE OF THE APPLICANT IN THE MEMBER STATE

I.1	I hereby confirm that /confirm on behalf of the sponsor (delete which is not applicable) that:
	 the information provided is complete;
	 the attached documents contain an accurate account of the information available;
	 the clinical trial will be conducted in accordance with the protocol; and
	 the clinical trial will be conducted, and SUSARs and result-related information will be reported, in accordance with the applicable legislation.
I.2	APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY (as stated in section C.1):
I.2 I.2.1	APPLICANT OF THE REQUEST FOR THE COMPETENT AUTHORITY (as stated in section C.1): Date:
I.2.1	Date:
I.2.1 I.2.2	Date: Signature ³¹ :

I.3.1	Date:
I.3.2	Signature ³² :

I.3.3 Print name:

ENDNOTES

¹ Any translation of the protocol should be assigned the same date and version as those in the original document.

² International Standard Randomised Controlled Trial Number. Sponsors may wish to use an International Standardised Random Controlled Trial Number (ISRCTN) to identify their trial in addition to the EudraCT number; for instance if their trial is part of a multinational trial with sites outside the Community. They can obtain the number and guidance from the Current Controlled Trials website http://www.controlled-trials.com/isrctn to which there is a link from the EudraCT database website http://eudract.ema.europa.eu.

When available they should provide it in Section A.6 of the application form. ³ US National Clinical Trial (NCT) Numbers required on the FDA clinical trial application form.

⁴ For a resubmission following previous withdrawal of an application or unfavourable opinion of an ethics committee, or previous withdrawal of an application or refusal of a request by the competent authority, enter a letter in the sequence, A for first resubmission, B for second, C for third et seq.

⁵ In accordance with Article 19 of Directive 2001/20/EC.

⁶ The contact point should give functional information rather than details of one "person", in order to avoid the need for update and maintenance of these contact details.

⁷ This requires a EudraLink account. (See https://eudract.ema.europa.eu/document.html for details)
 ⁸ According to national legislation.

⁹ Available from the Summary of Product Characteristics (SmPC)

¹⁰ According to the Community register on orphan medicinal products (Regulation (EC) n° 141/2000): <u>http://ec.europa.eu/enterprise/pharmaceuticals/register/index.htm</u>

¹¹ Committee for Medicinal Products for Human Use of the European Medicines Agency

¹² To be provided only when there is No trade name. This is the name routinely used by a sponsor to identify the IMP in the CT documentation (protocol, IB...).

¹³ To be provided only when there is No trade name. This is a code designated by the sponsor which represents the name routinely used by the sponsor to identify the product in the CT documentation. For example, a code may be used for combinations of drugs or drugs and devices.

¹⁴ Available from the Summary of Product Characteristics (SmPC).

¹⁵ Chemical Abstracts Service.

¹⁶ Complete also section D.4 Cell therapy as defined in Annex 1 part IV of Directive 2001/83/EC as amended.

¹⁷ Complete also section D.5 Gene Therapy as defined in Annex 1 part IV of Directive 2001/83/EC as amended.

 18 Complete also section D.6 - Tissue Engineered Product as defined in Article 2(1)(b) of

Regulation1394/2007/EC.

¹⁹ Complete also section D.7

²⁰ The mode of action should briefly describe the chemical, biochemical, immunological or biological means the IMP uses to effect its pharmaceutical action.

²¹ Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/2007 19 July 2007

²² In accordance with paragraph 38 of Annex 13 of Volume 4 of the Rules Governing Medical Products in the European Union.

²³ In the case of healthy volunteer trials, the intended indication for the product under development should be provided.

²⁴ Applicants are encouraged to provide the MedDRA lower level term if applicable and classification code. These can be accessed from the EMEA EudraCT website (<u>http://eudract.ema.europa.eu/</u>).

²⁵ Points to consider on the calculation and reporting of the prevalence of a condition for Orphan drug designation: COM/436/01 (<u>http://www.ema.europa.eu/htms/human/orphans/intro.htm</u>).

²⁶ The protocol will usually identify a single primary end point but there may be a co-primary end point in some cases and/or a number of secondary end points.

²⁷ The descriptions of the trial types provided are those recommended in preference to Phases. See page 5 of Community guideline CPMP/ICH/291/95. The development of a new indication after initial approval of a medicine should be considered as a new development plan.

²⁸ From the first inclusion until the last visit of the last subject.

²⁹ These numbers will be initial estimates. Applicants will not be required to update this information nor do they constitute an authorisation or restriction on the inclusion of these numbers of patients in the trial. The numbers of subjects whose inclusion is authorised are those set out in the authorised version of the protocol, or subsequent authorised amendments.

³⁰ Interactive Voice Response System: commonly used for randomisation of treatment and controlling the shipment of stock of product.

³¹ On an application to the Competent Authority only, the applicant to the Competent Authority needs to sign.

³² On an application to the Ethics Committee only, the applicant to the Ethics Committee needs to sign.